**ICD \-11**   
International 

Classification 

of Diseases 

for 

Mortality and 

Morbidity Statistics Eleventh Revision  
**Copyright page** 

International Classification of Diseases, Eleventh Revision (ICD-11) 

**© World Health Organization 2025** 

Some rights reserved. This work is available under the Creative Commons Attribution-NoDerivatives  3.0 IGO license (CC BY-ND 3.0 IGO; https://creativecommons.org/licenses/by-nd/3.0/igo/).  

Under the terms of this license, you may copy and redistribute the work, provided the work is  appropriately cited, as indicated below. In any use of this work, there should be no suggestion that  WHO endorses any specific organization, products or services. The use of the WHO logo is not  permitted. This license does not allow you to produce adaptations of the work (including  translations) without permission from WHO. 

Any mediation relating to disputes arising under the license shall be conducted in accordance with  the mediation rules of the World Intellectual Property Organization. 

This PDF version of ICD-11 was generated to support the user preference for viewing ICD-11 in a  portable format. The definitive version of ICD-11 is available from https://icd.who.int/browse11/l m/en. 

**Suggested citation**. International Classification of Diseases, Eleventh Revision (ICD-11). Geneva:  World Health Organization; 2025\. License: CC BY-ND 3.0 IGO. 

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party,  such as tables, figures or images, it is your responsibility to determine whether permission is needed  for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from  infringement of any third-party-owned component in the work rests solely with the user. 

**General disclaimers.** The designations employed and the presentation of the material in this  publication do not imply the expression of any opinion whatsoever on the part of WHO concerning  the legal status of any country, territory, city or area or of its authorities, or concerning the  delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate  border lines for which there may not yet be full agreement. 

The mention of specific companies or of certain manufacturers’ products does not imply that they  are endorsed or recommended by WHO in preference to others of a similar nature that are not  mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by  initial capital letters. 

All reasonable precautions have been taken by WHO to verify the information contained in this  publication. However, the published material is being distributed without warranty of any kind,  either expressed or implied. The responsibility for the interpretation and use of the material lies with  the reader. In no event shall WHO be liable for damages arising from its use. 

ICD-11 MMS 1   
Correct use of ICD-11 

Please refer to the reference guide for the correct use of ICD-11  

(https://icdcdn.who.int/icd11referenceguide/en/html/index.html ).  

To prevent the dilution of ICD’s purpose to provide a definitive standard for identifying health  information, ICD-11 may not be used for the purpose of developing or promoting a different  standard.  

The use of ICD-11 in software products is subject to the following license:  

https://icd.who.int/en/docs/ICD11-license.pdf. Under the terms of this license, users may not:  

• reproduce ICD-11 in part or whole and distribute it under a different name or without  attribution;  

• reproduce and distribute ICD-11 in part or whole without the ICD-11 codes;  • reproduce ICD-11 in part or whole without the ICD-11 URIs (not applicable for print  publications). 

Mappings or crosslinks between other classifications and terminologies and ICD-11 and/or  translations are not covered by the ICD-11 license and are subject to a separate written agreement  from WHO.  

Adding data fields to ICD-11 concepts is permitted, provided such additions are clearly identified as  additions that do not originate from WHO.  

Suggestions for changes to ICD-11 should be submitted as a proposal to the ICD-11 maintenance platform (https://icd.who.int/en).

2 ICD-11 MMS    
**TABLE OF CONTENTS** 

CHAPTER 01 ..........................................................................................................................................44 Certain infectious or parasitic diseases ................................................................................................44 Gastroenteritis or colitis of infectious origin (1A00‑1A40.Z)............................................................45 Bacterial intestinal infections (1A00‑1A0Z) ..................................................................................45 Bacterial foodborne intoxications (1A10‑1A1Z) ...........................................................................47 Viral intestinal infections (1A20‑1A2Z).........................................................................................48 Protozoal intestinal infections (1A30‑1A3Z).................................................................................49 Predominantly sexually transmitted infections (1A60‑1A9Z)...........................................................51 Syphilis (1A60‑1A6Z).....................................................................................................................51 Gonococcal infection (1A70‑1A7Z) ...............................................................................................54 Sexually transmissible infections due to chlamydia (1A80‑1A8Z)................................................55 Mycobacterial diseases (1B10‑1B2Z)................................................................................................58 Tuberculosis (1B10‑1B1Z) .............................................................................................................58 Certain staphylococcal or streptococcal diseases (1B40‑1B5Z)........................................................63 Acute rheumatic fever (1B40‑1B42) .............................................................................................63 Pyogenic bacterial infections of the skin or subcutaneous tissues (1B70‑1B7Z)..............................66 Certain zoonotic bacterial diseases (1B90‑1B9Z) .............................................................................70 Other bacterial diseases (1C10‑1C4Z)...............................................................................................73 Other diseases due to chlamydiae (1C20‑1C2Z)...........................................................................83 Rickettsioses (1C30‑1C3Z).............................................................................................................84 Human immunodeficiency virus disease (1C60‑1C62.Z) ..................................................................87 Viral infections of the central nervous system (1C80‑1C8Z) ............................................................92 Non-viral and unspecified infections of the central nervous system (1D00‑1D0Z)..........................95 Dengue (1D20‑1D2Z) ......................................................................................................................101 Certain arthropod-borne viral fevers (1D40‑1D4Z) ........................................................................101 Certain zoonotic viral diseases (1D60‑1D6Z)..................................................................................107 Certain other viral diseases (1D80‑1E1Z)........................................................................................112 Viral infection of unspecified site (1D90‑1D9Z)..........................................................................115 Influenza (1E30‑1E32).....................................................................................................................116 Viral hepatitis (1E50‑1E5Z)..............................................................................................................117 Viral infections characterised by skin or mucous membrane lesions (1E70‑1F0Z) ........................120 Infections due to poxvirus (1E70‑1E7Z)......................................................................................120 Human papillomavirus infection of skin or mucous membrane (1E80‑1E8Z)............................122

ICD-11 MMS 3   
Varicella zoster virus infections (1E90‑1E91.Z)...........................................................................123 Mycoses (1F20‑1F2Z)......................................................................................................................128 Parasitic diseases (1F40‑1G2Z) .......................................................................................................141 

Malaria (1F40‑1F4Z)....................................................................................................................141 Nonintestinal protozoal diseases (1F50‑1F5Z)............................................................................143 Helminthiases (1F60‑1F9Z) .........................................................................................................148 

Diseases due to nematodes (1F60‑1F6Z)................................................................................148 Diseases due to cestodes (1F70‑1F7Z)....................................................................................154 Diseases due to trematodes (1F80‑1F8Z)...............................................................................157 

Infestations by ectoparasites (1G00‑1G0Z) ................................................................................159 Sepsis (1G40‑1G41).........................................................................................................................163 Sequelae of infectious diseases (1G80‑1G8Z).................................................................................164 

CHAPTER 02 ........................................................................................................................................166 Neoplasms...........................................................................................................................................166 Neoplasms of central nervous system or related structures (2A00‑2A0Z) ....................................166 Neoplasms of haematopoietic or lymphoid tissues (2A20‑2B3Z) ..................................................169 Myeloproliferative neoplasms (2A20‑2A2Z)...............................................................................169 Myelodysplastic syndromes (2A30‑2A3Z)...................................................................................171 Myelodysplastic and myeloproliferative neoplasms (2A40‑2A4Z).............................................173 

Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or  FGFR1 (2A50‑2A5Z).....................................................................................................................174 

Precursor lymphoid neoplasms (2A70‑2A7Z) .............................................................................177 Mature B-cell neoplasms (2A80‑2A8Z).......................................................................................178 Mature T-cell or NK-cell neoplasms (2A90‑2B2Z).......................................................................184 

Mature T-cell or NK-cell lymphomas and lymphoproliferative disorders, primary cutaneous  specified types (2B00‑2B0Z) ...................................................................................................186 

Malignant neoplasms, except primary neoplasms of lymphoid, haematopoietic, central nervous  system or related tissues (2B50‑2E2Z) ...........................................................................................191 

Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid,  haematopoietic, central nervous system or related tissues (2B50‑2D3Z) .................................191 

Malignant mesenchymal neoplasms (2B50‑2B5Z) .................................................................191 Malignant neoplasms of lip, oral cavity or pharynx (2B60‑2B6Y)...........................................196 Malignant neoplasms of digestive organs (2B70‑2C1Z) .........................................................202 

Malignant neoplasms of intestine (2B80‑2C0Z) .................................................................204 Malignant neoplasms of large intestine (2B90‑2B9Y) ....................................................205

4 ICD-11 MMS    
Malignant neoplasms of middle ear, respiratory or intrathoracic organs (2C20‑2C2Z).........212 Malignant neoplasms of skin (2C30‑2C3Z) .............................................................................216 Malignant neoplasms of peripheral nerves or autonomic nervous system (2C40‑2C4Z) ......219 Malignant neoplasms of retroperitoneum, peritoneum or omentum (2C50‑2C53.Z)...........220 Malignant neoplasms of breast (2C60‑2C6Z) .........................................................................221 Malignant neoplasms of female genital organs (2C70‑2C7Z).................................................222 Malignant neoplasms of male genital organs (2C80‑2C8Z)....................................................228 Malignant neoplasms of urinary tract (2C90‑2C9Z)................................................................230 Malignant neoplasms of eye or ocular adnexa (2D00‑2D0Z) .................................................232 Malignant neoplasms of endocrine glands (2D10‑2D1Z) .......................................................234 

Malignant neoplasms of ill-defined or unspecified primary sites (2D40‑2D4Z).........................237 Malignant neoplasm metastases (2D50‑2E2Z)...........................................................................237 Malignant neoplasm metastasis in lymph nodes (2D60‑2D6Z)..............................................238 Malignant neoplasm metastasis in thoracic or respiratory organs (2D70‑2D7Z)...................238 Malignant neoplasm metastasis in digestive system (2D80‑2D8Z)........................................239 Malignant neoplasm metastasis in retroperitoneum or peritoneum (2D90‑2D91)...............239 Malignant neoplasm metastasis in other specified sites (2E00‑2E0Y) ...................................239 

In situ neoplasms, except of lymphoid, haematopoietic, central nervous system or related tissues  (2E60‑2E6Z).....................................................................................................................................240 

Benign neoplasms, except of lymphoid, haematopoietic, central nervous system or related tissues  (2E80‑2F3Z).....................................................................................................................................246 

Benign mesenchymal neoplasms (2E80‑2E8Z) ...........................................................................246 Benign neoplasms except of mesenchymal origin (2E90‑2F3Z) .................................................250 Benign neoplasm of middle ear, respiratory or intrathoracic organs (2F00‑2F01)................253 Benign cutaneous neoplasms (2F20‑2F2Z).............................................................................254 

Neoplasms of uncertain behaviour, except of lymphoid, haematopoietic, central nervous system  or related tissues (2F70‑2F7Z) ........................................................................................................260 

Neoplasms of unknown behaviour, except of lymphoid, haematopoietic, central nervous system  or related tissues (2F90‑2F9Z) ........................................................................................................262 

CHAPTER 03 ........................................................................................................................................263 Diseases of the blood or blood-forming organs .................................................................................263 Anaemias or other erythrocyte disorders (3A00‑3A9Z) .................................................................264 Nutritional or metabolic anaemias (3A00‑3A03.Y).....................................................................264 Haemolytic anaemias (3A10‑3A4Z).............................................................................................268 Congenital haemolytic anaemia (3A10‑3A1Y) ........................................................................268

ICD-11 MMS 5   
Acquired haemolytic anaemia (3A20‑3A2Z)...........................................................................269 Pure red cell aplasia (3A60‑3A6Z)...............................................................................................275 Polycythaemia (3A80‑3A8Z)........................................................................................................279 

Coagulation defects, purpura or other haemorrhagic or related conditions (3B10‑3B6Z)............281 Coagulation defects (3B10‑3B4Z) ...............................................................................................281 Congenital or constitutional haemorrhagic condition (3B10‑3B1Z).......................................281 Haemorrhagic diseases due to acquired coagulation factor defects (3B20‑3B2Y) ................283 Fibrinolytic defects (3B50‑3B51).................................................................................................284 Diseases of spleen (3B80‑3B8Z)......................................................................................................291 CHAPTER 04 ........................................................................................................................................295 Diseases of the immune system .........................................................................................................295 Primary immunodeficiencies (4A00‑4A0Z).....................................................................................295 Nonorgan specific systemic autoimmune disorders (4A40‑4A4Z) .................................................299 Autoinflammatory disorders (4A60‑4A6Z) .....................................................................................308 Allergic or hypersensitivity conditions (4A80‑4A8Z).......................................................................310 Immune system disorders involving white cell lineages (4B00‑4B0Z)............................................317 Certain disorders involving the immune system (4B20‑4B2Y) .......................................................319 CHAPTER 05 ........................................................................................................................................322 Endocrine, nutritional or metabolic diseases.....................................................................................322 Endocrine diseases (5A00‑5B3Z).....................................................................................................322 Disorders of the thyroid gland or thyroid hormones system (5A00‑5A0Z)................................322 Diabetes mellitus (5A10‑5A2Y)...................................................................................................327 Acute complications of diabetes mellitus (5A20‑5A2Y)..........................................................329 Other disorders of glucose regulation or pancreatic internal secretion (5A40‑5A4Z) ...............331 Disorders of the parathyroids or parathyroid hormone system (5A50‑5A5Z) ...........................332 Disorders of the pituitary hormone system (5A60‑5A6Z) ..........................................................334 Disorders of the adrenal glands or adrenal hormone system (5A70‑5A7Z)...............................337 Disorders of the gonadal hormone system (5A80‑5A8Z) ...........................................................340 Certain disorders of puberty (5A90‑5A9Z)..................................................................................342 Polyglandular dysfunction (5B00‑5B0Z)......................................................................................343 Endocrine disorders, not elsewhere classified (5B10‑5B12) ......................................................343 Nutritional disorders (5B50‑5C3Z)..................................................................................................344 Undernutrition (5B50‑5B7Z) .......................................................................................................344 Sequelae of malnutrition or certain specified nutritional deficiencies (5B60‑5B6Z) .............355

6 ICD-11 MMS    
Overweight, obesity or specific nutrient excesses (5B80‑5C1Z).................................................356 Overweight or obesity (5B80‑5B81.Z).....................................................................................356 Certain specified nutrient excesses (5B90‑5B9Z) ...................................................................358 

Metabolic disorders (5C50‑5D2Z)...................................................................................................361 Inborn errors of metabolism (5C50‑5C5Z)..................................................................................361 Disorders of metabolite absorption or transport (5C60‑5C6Z) ..................................................378 Disorders of fluid, electrolyte or acid-base balance (5C70‑5C7Z) ..............................................384 Disorders of lipoprotein metabolism or certain specified lipidaemias (5C80‑5C8Z)..................386 Other metabolic disorders (5D00‑5D0Y) ....................................................................................389 

Postprocedural endocrine or metabolic disorders (5D40‑5D46) ...................................................391 CHAPTER 06 ........................................................................................................................................393 Mental, behavioural or neurodevelopmental disorders ....................................................................393 

Neurodevelopmental disorders (6A00‑6A0Z).................................................................................394 Schizophrenia or other primary psychotic disorders (6A20‑6A2Z).................................................405 Catatonia (6A40‑6A4Z)....................................................................................................................414 Mood disorders (6A60‑6A8Z)..........................................................................................................416 

Bipolar or related disorders (6A60‑6A6Z)...................................................................................416 Depressive disorders (6A70‑6A7Z)..............................................................................................425 Anxiety or fear-related disorders (6B00‑6B0Z)...............................................................................434 Obsessive-compulsive or related disorders (6B20‑6B2Z)...............................................................437 Disorders specifically associated with stress (6B40‑6B4Z) .............................................................442 Dissociative disorders (6B60‑6B6Z) ................................................................................................445 Feeding or eating disorders (6B80‑6B8Z) .......................................................................................451 Elimination disorders (6C00‑6C0Z) .................................................................................................455 Disorders of bodily distress or bodily experience (6C20‑6C2Z)......................................................457 Disorders due to substance use or addictive behaviours (6C40‑6C5Z)..........................................459 Disorders due to substance use (6C40‑6C4Z).............................................................................459 Disorders due to addictive behaviours (6C50‑6C5Z) ..................................................................560 Impulse control disorders (6C70‑6C7Z) ..........................................................................................563 Disruptive behaviour or dissocial disorders (6C90‑6C9Z)...............................................................565 Personality disorders and related traits (6D10‑6D11.5).................................................................568 Paraphilic disorders (6D30‑6D3Z)...................................................................................................571 Factitious disorders (6D50‑6D5Z) ...................................................................................................573 Neurocognitive disorders (6D70‑6E0Z)...........................................................................................574

ICD-11 MMS 7   
Dementia (6D80‑6D8Z)...............................................................................................................579 

Mental or behavioural disorders associated with pregnancy, childbirth or the puerperium  (6E20‑6E2Z).....................................................................................................................................589 

Secondary mental or behavioural syndromes associated with disorders or diseases classified  elsewhere (6E60‑6E6Z) ...................................................................................................................592 

CHAPTER 07 ........................................................................................................................................600 Sleep-wake disorders..........................................................................................................................600 Insomnia disorders (7A00‑7A0Z) ....................................................................................................601 Hypersomnolence disorders (7A20‑7A2Z)......................................................................................602 Sleep-related breathing disorders (7A40‑7A4Z).............................................................................605 Circadian rhythm sleep-wake disorders (7A60‑7A6Z) ....................................................................611 Sleep-related movement disorders (7A80‑7A8Z)...........................................................................613 Parasomnia disorders (7B00‑7B0Z) ................................................................................................615 CHAPTER 08 ........................................................................................................................................619 Diseases of the nervous system..........................................................................................................619 Movement disorders (8A00‑8A0Z) .................................................................................................620 Disorders with neurocognitive impairment as a major feature (8A20‑8A2Z)................................631 Multiple sclerosis or other white matter disorders (8A40‑8A4Z)...................................................632 Epilepsy or seizures (8A60‑8A6Z)....................................................................................................639 Headache disorders (8A80‑8A8Z)...................................................................................................647 Cerebrovascular diseases (8B00‑8B2Z)...........................................................................................650 Intracranial haemorrhage (8B00‑8B0Z) ......................................................................................650 Cerebral ischaemia (8B10‑8B1Z).................................................................................................652 Spinal cord disorders excluding trauma (8B40‑8B4Z).....................................................................661 Motor neuron diseases or related disorders (8B60‑8B6Z) .............................................................662 Disorders of nerve root, plexus or peripheral nerves (8B80‑8C4Z)................................................666 Disorders of cranial nerves (8B80‑8B8Z) ....................................................................................666 Nerve root or plexus disorders (8B90‑8B9Z) ..............................................................................668 Polyneuropathy (8C00‑8C0Z)......................................................................................................670 Mononeuropathy (8C10‑8C1Z)...................................................................................................672 Hereditary neuropathy (8C20‑8C2Z)...........................................................................................674 Diseases of neuromuscular junction or muscle (8C60‑8D0Z).........................................................676 Myasthenia gravis or certain specified neuromuscular junction disorders (8C60‑8C6Z)...........676 Primary disorders of muscles (8C70‑8C7Z).................................................................................677

8 ICD-11 MMS    
Secondary myopathies (8C80‑8C8Z)...........................................................................................684 Cerebral palsy (8D20‑8D2Z)............................................................................................................686 Nutritional or toxic disorders of the nervous system (8D40‑8D4Z)................................................688 Disorders of cerebrospinal fluid pressure or flow (8D60‑8D6Z).....................................................691 Disorders of autonomic nervous system (8D80‑8D8Z)...................................................................694 Human prion diseases (8E00‑8E0Z) ................................................................................................697 Disorders of consciousness (8E20‑8E2Z) ........................................................................................699 Certain disorders of the nervous system (8E40‑8E4A.Z)................................................................699 Postprocedural disorders of the nervous system (8E60‑8E66) ......................................................704 

CHAPTER 09 ........................................................................................................................................706 Diseases of the visual system..............................................................................................................706 Disorders of the ocular adnexa or orbit (9A00‑9A4Z).....................................................................707 Disorders of eyelid or peri-ocular area (9A00‑9A0Z)..................................................................707 Disorders of lacrimal apparatus (9A10‑9A1Z).............................................................................713 Disorders of orbit (9A20‑9A2Z)...................................................................................................714 Disorders of the eyeball \- anterior segment (9A60‑9B3Z)..............................................................717 Disorders of conjunctiva (9A60‑9A6Z)........................................................................................717 Disorders of the cornea (9A70‑9A7Z) .........................................................................................720 Disorders of the anterior chamber (9A80‑9A8Z)........................................................................723 Disorders of the anterior uvea (9A90‑9A9Z)...............................................................................723 Functional disorders of the pupil (9B00‑9B0Z)...........................................................................725 Disorders of lens (9B10‑9B1Z) ....................................................................................................726 Disorders of the eyeball \- posterior segment (9B50‑9C0Z) ............................................................728 Disorders of sclera (9B50‑9B5Z)..................................................................................................728 Disorders of the choroid (9B60‑9B6Z) ........................................................................................728 Disorders of the retina (9B70‑9B7Z)...........................................................................................730 Disorders of the vitreous body (9B80‑9B8Z) ..............................................................................736 Disorders of the eyeball affecting both anterior and posterior segments (9C20‑9C2Z) ................737 Disorders of the visual pathways or centres (9C40‑9C4Z)..............................................................738 Glaucoma or glaucoma suspect (9C60‑9C6Z).................................................................................740 Strabismus or ocular motility disorders (9C80‑9C8Z).....................................................................744 Disorders of refraction or accommodation (9D00‑9D0Z)...............................................................749 Postprocedural disorders of eye or ocular adnexa (9D20‑9D25) ...................................................751 Impairment of visual functions (9D41‑9D7Z)..................................................................................751

ICD-11 MMS 9   
Subjective visual experiences (9D50‑9D5Z)................................................................................753 Vision impairment (9D90‑9D9Z) .....................................................................................................754 CHAPTER 10 ........................................................................................................................................757 Diseases of the ear or mastoid process..............................................................................................757 Diseases of external ear (AA00‑AA6Z)............................................................................................758 Infectious diseases of external ear (AA00‑AA0Z)........................................................................758 Otitis externa (AA10‑AA3Z).........................................................................................................759 Noninfectious inflammation of external ear (AA10‑AA1Z).....................................................759 Noninflammatory disorders of the external ear (AA40‑AA4Z)...................................................760 Diseases of middle ear or mastoid (AA80‑AB1Z)............................................................................761 Otitis media (AA80‑AB0Z)...........................................................................................................761 Nonsuppurative otitis media (AA80‑AA8Z).............................................................................761 Suppurative otitis media (AA90‑AA9Z)...................................................................................761 Diseases of inner ear (AB30‑AB3Z) .................................................................................................765 Disorders with hearing impairment (AB50‑AB5Z) ..........................................................................769 Disorders of ear, not elsewhere classified (AB70‑AB7Y) ................................................................770 Postprocedural disorders of ear or mastoid process (AB90‑AB93)................................................771 CHAPTER 11 ........................................................................................................................................772 Diseases of the circulatory system......................................................................................................772 Hypertensive diseases (BA00‑BA04.Z)............................................................................................773 Hypotension (BA20‑BA2Z) ..............................................................................................................775 Ischaemic heart diseases (BA40‑BA6Z)...........................................................................................775 Acute ischaemic heart disease (BA40‑BA4Z) ..............................................................................775 Chronic ischaemic heart disease (BA50‑BA5Z) ...........................................................................777 Diseases of coronary artery (BA81‑BA8Z).......................................................................................780 Pulmonary heart disease or diseases of pulmonary circulation (BB00‑BB0Z)................................781 Pericarditis (BB20‑BB2Z).................................................................................................................784 Acute or subacute endocarditis (BB40‑BB4Z).................................................................................785 Heart valve diseases (BB60‑BC0Z) ..................................................................................................786 Mitral valve disease (BB60‑BB6Z)...............................................................................................786 Aortic valve disease (BB70‑BB7Z) ...............................................................................................788 Tricuspid valve disease (BB80‑BB8Z) ..........................................................................................789 Pulmonary valve disease (BB90‑BB9Z) .......................................................................................790 Diseases of the myocardium or cardiac chambers (BC40‑BC4Z)....................................................794

10 ICD-11 MMS    
Cardiac arrhythmia (BC60‑BC9Z) ....................................................................................................799 Ventricular rhythm disturbance (BC70‑BC7Z) ............................................................................802 Supraventricular rhythm disturbance (BC80‑BC8Z)....................................................................803 

Heart failure (BD10‑BD1Z) ..............................................................................................................807 Diseases of arteries or arterioles (BD30‑BD5Z) ..............................................................................808 Chronic arterial occlusive disease (BD40‑BD4Z).........................................................................809 Diseases of veins (BD70‑BD7Z) .......................................................................................................815 Disorders of lymphatic vessels or lymph nodes (BD90‑BD9Z)........................................................820 Postprocedural disorders of circulatory system (BE10‑BE1F.1) .....................................................823 CHAPTER 12 ........................................................................................................................................828 Diseases of the respiratory system.....................................................................................................828 Upper respiratory tract disorders (CA00‑CA0Z)..............................................................................829 Certain lower respiratory tract diseases (CA20‑CA2Z) ...................................................................839 Lung infections (CA40‑CA4Z) ..........................................................................................................846 Lung diseases due to external agents (CA60‑CA8Z)........................................................................853 Pneumonitis (CA70‑CA7Z)...........................................................................................................855 Respiratory diseases principally affecting the lung interstitium (CB00‑CB0Z) ...............................859 Pleural, diaphragm or mediastinal disorders (CB20‑CB2Z).............................................................865 Postprocedural disorders of the respiratory system (CB60‑CB64).................................................870 CHAPTER 13 ........................................................................................................................................872 Diseases of the digestive system ........................................................................................................872 Diseases or disorders of orofacial complex (DA00‑DA0Z) ..............................................................873 Diseases of oesophagus (DA20‑DA2Z)............................................................................................891 Diseases of the stomach or the duodenum (DA40‑DA7Z)..............................................................899 Diseases of stomach (DA40‑DA4Z) .............................................................................................899 Diseases of duodenum (DA50‑DA5Z)..........................................................................................904 Ulcer of stomach or duodenum (DA60‑DA63.Z).........................................................................908 Diseases of small intestine (DA90‑DA9Z)........................................................................................912 Diseases of appendix (DB10‑DB1Z).................................................................................................920 Diseases of large intestine (DB30‑DB3Z) ........................................................................................922 Diseases of anal canal (DB50‑DB7Z) ...............................................................................................930 Acquired anatomical alterations of the anal canal (DB50‑DB5Z) ...............................................930 Haemorrhoids or perianal venous conditions (DB60‑DB6Z).......................................................931 Diseases of liver (DB90‑DB9Z).........................................................................................................934

ICD-11 MMS 11   
Diseases of gallbladder or biliary tract (DC10‑DC1Z)......................................................................946 Diseases of pancreas (DC30‑DC3Z).................................................................................................949 Diseases of peritoneum (DC50‑DC5Z) ............................................................................................952 Diverticular disease of intestine (DC70‑DD1Z) ...............................................................................954 

Diverticular disease of small intestine (DC70‑DC72.Z) ...............................................................954 Diverticular disease of large intestine (DC80‑DC82.Z)................................................................956 Diverticular disease of intestine of overlapping sites (DC90‑DC90)...........................................957 Diverticular disease of unspecified part of intestine (DD00‑DD02.Z).........................................957 

Ischaemic vascular disorders of intestine (DD30‑DD3Z).................................................................958 Hernias (DD50‑DD5Z)......................................................................................................................959 Inflammatory bowel diseases (DD70‑DD7Z)...................................................................................961 Functional gastrointestinal disorders (DD90‑DD9Z).......................................................................963 Postprocedural disorders of digestive system (DE10‑DE13) ..........................................................968 

CHAPTER 14 ........................................................................................................................................970 Diseases of the skin.............................................................................................................................970 Certain skin disorders attributable to infection or infestation (EA00‑EA6Y)..................................971 Certain skin disorders attributable to viral infection (EA00‑EA3Z).............................................971 Viral exanthems (EA00‑EA0Y) .................................................................................................971 Certain dermatoses with suspected viral aetiology (EA10‑EA12) ..........................................972 Dermatoses from distant or systemic viral infection (EA20‑EA20) ........................................972 Certain skin disorders attributable to bacterial infection (EA40‑EA5Z)......................................973 Predominantly tropical or subtropical bacterial infections affecting skin (EA40‑EA40).........973 Inflammatory dermatoses (EA80‑EB7Y) .........................................................................................976 Dermatitis or eczema (EA80‑EA8Z).............................................................................................976 Papulosquamous dermatoses (EA90‑EA95) ...............................................................................982 Urticaria, angioedema or other urticarial disorders (EB00‑EB0Y)..............................................987 Inflammatory erythemas and other reactive inflammatory dermatoses (EB10‑EB31)..............989 Neutrophilic dermatoses (EB20‑EB2Y)....................................................................................991 Immunobullous diseases of the skin (EB40‑EB4Y)......................................................................992 Cutaneous lupus erythematosus (EB50‑EB5Z)............................................................................994 Scarring or sclerosing inflammatory dermatoses (EB60‑EB61.Z) ...............................................995 Metabolic or nutritional disorders affecting the skin (EB90‑EB9Y)................................................997 Genetic or developmental disorders affecting the skin (EC10‑EC7Y)...........................................1001 Genetic syndromes affecting the skin (EC10‑EC1Y)..................................................................1001

12 ICD-11 MMS    
Genetically-determined epidermolysis bullosa (EC30‑EC3Z)....................................................1005 Genetic disorders affecting dermal collagen, elastin or other matrix proteins (EC40‑EC4Y)...1006 Specified developmental anomalies affecting the skin (EC50‑EC5Y) .......................................1007 

Sensory or psychological disorders affecting the skin (EC90‑ED3Y).............................................1007 Disturbances of cutaneous sensation (EC90‑EC9Y) ..................................................................1007 Mental conditions affecting the skin (ED00‑ED2Y)...................................................................1010 

Self-inflicted skin disorders (ED00‑ED0Y) .............................................................................1010 Neurological conditions affecting the skin (ED30‑ED3Y)..........................................................1011 Skin disorders involving specific cutaneous structures (ED50‑EG02)...........................................1012 Disorders of the epidermis and epidermal appendages (ED50‑EE21)......................................1012 Disorders of epidermal keratinisation (ED50‑ED5Y).............................................................1012 Disorders of skin colour (ED60‑ED6Y)...................................................................................1014 Disorders of hair (ED70‑ED7Y) ..............................................................................................1017 Disorders of the hair follicle (ED80‑ED9Y) ............................................................................1021 Acne and related disorders (ED80‑ED81.Z).......................................................................1021 Disorders of eccrine sweat glands or sweating (EE00‑EE0Y)................................................1025 Disorders of the nail or perionychium (EE10‑EE1Z)..............................................................1026 Disorders of epidermal integrity (EE20‑EE21) ......................................................................1029 Disorders of the dermis or subcutis (EE40‑EF0Y)......................................................................1030 Disorders of cutaneous connective tissue (EE40‑EE7Y)........................................................1030 Poikiloderma (EE50‑EE50).................................................................................................1031 Fibromatoses or keloids (EE60‑EE6Z) ...............................................................................1032 Histiocytic-granulomatous disorders of the skin (EE80‑EE8Z)..............................................1033 

Benign dermal lymphocytic or lymphoplasmacytic infiltrations or proliferations (EE90‑EE91) ..............................................................................................................................................1034 

Disorders of subcutaneous fat (EF00‑EF0Y)..........................................................................1034 Disorders of cutaneous blood and lymphatic vessels (EF20‑EG02)..........................................1036 Malformations involving cutaneous blood vessels (EF20‑EF2Z)...........................................1036 Purpura or bruising (EF30‑EF3Z)...........................................................................................1037 Dermatoses attributable to hyperviscosity or microvascular occlusion (EF50‑EF5Y) ..........1039 Dermatoses resulting from vascular insufficiency (EF60‑EF9Y)............................................1039 Dermatoses due to venous disease (EF70‑EF7Z)..............................................................1039 Functional vascular disorders of the skin (EG00‑EG02)........................................................1039 Skin disorders involving certain specific body regions (EG30‑EG9Z)............................................1040

ICD-11 MMS 13   
Skin disorders involving the head and neck (EG30‑EG4Z) ........................................................1040 Disorders of the external ear involving the skin (EG40‑EG4Z)..............................................1041 Inflammatory disorders of the external ear (EG40‑EG4Z)................................................1041 Skin disorders involving the genital and perianal regions (EG60‑EG7Y)...................................1042 Dermatoses of the anus, perianal area or perineum (EG60‑EG63.Z) ...................................1042 Skin disorders associated with pregnancy, the neonatal period or infancy (EH10‑EH40.Z) ........1043 Skin disorders specific to the perinatal or neonatal period (EH10‑EH3Y) ................................1043 Neonatal skin infection (EH10‑EH1Z)....................................................................................1043 Adverse cutaneous reactions to medication (EH60‑EH7Z)...........................................................1045 Drug eruptions (EH60‑EH6Z).....................................................................................................1045 Skin disorders provoked by external factors (EH90‑EK5Y) ...........................................................1050 Dermatoses provoked or exacerbated by exposure to cold (EJ0Y‑EJ0Y)..................................1053 Dermatoses provoked by heat or electricity (EJ10‑EJ1Y) .........................................................1053 Dermatoses provoked by light or UV radiation (EJ20‑EJ6Y) .....................................................1054 Chronic effects of ultraviolet radiation on the skin (EJ20‑EJ2Y)...........................................1054 Acute effects of ultraviolet radiation on normal skin (EJ40‑EJ4Z)........................................1055 Dermatoses due to ionizing radiation (EJ71‑EJ7Z)....................................................................1056 Phototoxic reactions to skin contact with photoactive agents (EK20‑EK2Z)............................1060 Benign proliferations, neoplasms and cysts of the skin (EK70‑EK71.Z)........................................1061 Disorders of the skin of uncertain or unpredictable malignant potential (EK90‑EK92) ...............1063 Cutaneous markers of internal disorders (EL10‑EL3Y) .................................................................1065 Cutaneous markers of internal malignancy (EL10‑EL1Y)..........................................................1065 Postprocedural disorders of the skin (EL50‑EL80)........................................................................1065 Adverse cutaneous effects of therapeutic ionizing irradiation (EL60‑EL63).............................1066 Complications of cutaneous cosmetic procedures (EL73‑EL73.6)............................................1067 CHAPTER 15 ......................................................................................................................................1069 Diseases of the musculoskeletal system or connective tissue .........................................................1069 Arthropathies (FA00‑FA5Z)...........................................................................................................1070 Osteoarthritis (FA00‑FA0Z) .......................................................................................................1070 Infection related arthropathies (FA10‑FA1Z)............................................................................1071 Inflammatory arthropathies (FA20‑FA2Z).................................................................................1073 Certain specified joint disorders or deformities of limbs (FA30‑FA3Z).....................................1078 Conditions associated with the spine (FA70‑FB1Z).......................................................................1083 Structural disorders of spine (FA70‑FA7Z)................................................................................1083

14 ICD-11 MMS    
Degenerative condition of spine (FA80‑FA8Z)..........................................................................1084 Inflammation of spine (FA90‑FA9Z)..........................................................................................1087 Spondylopathies (FB00‑FB0Z)...................................................................................................1088 

Soft tissue disorders (FB30‑FB6Z).................................................................................................1089 Disorders of muscles (FB30‑FB3Z) ............................................................................................1089 Disorders of synovium or tendon (FB40‑FB4Z).........................................................................1091 Miscellaneous specified soft tissue disorders (FB50‑FB56.6)...................................................1093 

Osteopathies or chondropathies (FB80‑FB8Z)..............................................................................1097 CHAPTER 16 ......................................................................................................................................1104 Diseases of the genitourinary system...............................................................................................1104 

Diseases of the female genital system (GA00‑GA6Z) ...................................................................1105 Inflammatory disorders of the female genital tract (GA00‑GA0Z) ...........................................1105 Noninflammatory disorders of female genital tract (GA12‑GA1Z)...........................................1111 Abnormal uterine or vaginal bleeding (GA20‑GA2Z)................................................................1117 Dermatoses of female genitalia (GA40‑GA4Y)..........................................................................1127 

Diseases of the male genital system (GA80‑GB0Z).......................................................................1128 Dermatoses of male genitalia (GA80‑GA81.Y)..........................................................................1128 Diseases of prostate (GA90‑GA91.Z) ........................................................................................1129 

Disorders of breast (GB20‑GB2Y)..................................................................................................1136 Diseases of the urinary system (GB40‑GC2Z) ...............................................................................1138 Glomerular diseases (GB40‑GB4Z)............................................................................................1138 Renal tubulo-interstitial diseases (GB50‑GB5Z)........................................................................1140 Kidney failure (GB60‑GB6Z) ......................................................................................................1143 Urolithiasis (GB70‑GB7Z) ..........................................................................................................1145 Cystic or dysplastic kidney disease (GB80‑GB8Z) .....................................................................1147 Certain specified diseases of urinary system (GC00‑GC0Y)......................................................1152 Other conditions of the genitourinary system (GC40‑GC51.Z).....................................................1158 Female pelvic floor dysfunction (GC40‑GC4Z)..........................................................................1158 Postprocedural disorders of genitourinary system (GC70‑GC7C) ................................................1164 CHAPTER 17 ......................................................................................................................................1166 Conditions related to sexual health..................................................................................................1166 Sexual dysfunctions (HA00‑HA0Z) ................................................................................................1166 Sexual pain disorders (HA20‑HA2Z)..............................................................................................1172 Gender incongruence (HA60‑HA6Z) .............................................................................................1174

ICD-11 MMS 15   
CHAPTER 18 ......................................................................................................................................1176 Pregnancy, childbirth or the puerperium .........................................................................................1176 Abortive outcome of pregnancy (JA00‑JA0Z) ...............................................................................1176 

Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium  (JA20‑JA2Z)....................................................................................................................................1182 

Obstetric haemorrhage (JA40‑JA4Z).............................................................................................1185 Certain specified maternal disorders predominantly related to pregnancy (JA60‑JA6Z).............1188 Maternal care related to the fetus, amniotic cavity or possible delivery problems (JA80‑JA8Z).1194 Complications of labour or delivery (JB00‑JB0Z) ..........................................................................1199 Delivery (JB20‑JB2Z)......................................................................................................................1208 Complications predominantly related to the puerperium (JB40‑JB4Z)........................................1210 Certain obstetric conditions, not elsewhere classified (JB60‑JB6Z) .............................................1214 

CHAPTER 19 ......................................................................................................................................1220 Certain conditions originating in the perinatal period .....................................................................1220 

Fetus or newborn affected by maternal factors or by complications of pregnancy, labour or  delivery (KA00‑KA0Z) ....................................................................................................................1221 

Disorders of newborn related to length of gestation or fetal growth (KA20‑KA2Z) ....................1231 Birth injury (KA40‑KA4Z)...............................................................................................................1237 Infections of the fetus or newborn (KA60‑KA6Z)..........................................................................1243 Haemorrhagic or haematological disorders of fetus or newborn (KA80‑KA8Z)...........................1247 Neurological disorders specific to the perinatal or neonatal period (KB00‑KB0Z).......................1254 Respiratory disorders specific to the perinatal or neonatal period (KB20‑KB2Z).........................1256 Cardiovascular disorders present in the perinatal or neonatal period (KB40‑KB4Z) ...................1262 Transitory endocrine or metabolic disorders specific to fetus or newborn (KB60‑KB6Z)............1263 Digestive system disorders of fetus or newborn (KB80‑KB8Z).....................................................1268 Genitourinary system disorders specific to the perinatal or neonatal period (KC00‑KC0Z) ........1271 Disorders involving the integument of fetus or newborn (KC20‑KC9Z) .......................................1271 

Skin disorders associated with prematurity (KC30‑KC3Y) ........................................................1273 Iatrogenic injuries involving the skin of the neonate (KC50‑KC7Y) ..........................................1274 Postnatal iatrogenic skin injury (KC50‑KC5Z)........................................................................1274 Disturbances of temperature regulation of newborn (KD10‑KD1Z).............................................1275 Certain disorders originating in the perinatal period (KD30‑KD3Y)..............................................1275 CHAPTER 20 ......................................................................................................................................1281 Developmental anomalies................................................................................................................1281

16 ICD-11 MMS    
Structural developmental anomalies primarily affecting one body system (LA00‑LD0Z)............1281 Structural developmental anomalies of the nervous system (LA00‑LA0Z) ..............................1281 Structural developmental anomalies of the eye, eyelid or lacrimal apparatus (LA10‑LA1Z)...1289 Structural developmental anomalies of the ear (LA20‑LA2Z) ..................................................1294 Structural developmental anomalies of the face, mouth or teeth (LA30‑LA5Z) ......................1295 

Clefts of lip, alveolus or palate (LA40‑LA4Z) .........................................................................1298 Structural developmental anomalies of the neck (LA60‑LA6Z) ................................................1300 Structural developmental anomalies of the respiratory system (LA70‑LA7Z)..........................1300 Structural developmental anomalies of the circulatory system (LA80‑LA9Z) ..........................1304 

Structural developmental anomaly of heart or great vessels (LA80‑LA8Z)..........................1304 

Structural developmental anomalies of the diaphragm, abdominal wall or umbilical cord  (LB00‑LB0Z)...............................................................................................................................1326 

Structural developmental anomalies of the digestive tract (LB10‑LB1Z).................................1327 

Structural developmental anomalies of the liver, biliary tract, pancreas or spleen (LB20‑LB2Z) ..................................................................................................................................................1333 

Structural developmental anomalies of the urinary system (LB30‑LB3Z)................................1335 Structural developmental anomalies of the female genital system (LB40‑LB4Z).....................1339 Structural developmental anomalies of the male genital system (LB50‑LB5Z)........................1344 Structural developmental anomalies of the breast (LB60‑LB6Z)..............................................1347 Structural developmental anomalies of the skeleton (LB70‑LB9Z) ..........................................1347 

Congenital deformities of fingers or toes (LB80‑LB81.Z)......................................................1354 Structural developmental anomalies of the skin (LC00‑LC7Z)..................................................1360 Developmental hamartomata of the epidermis and epidermal appendages (LC00‑LC0Y)..1360 Developmental anomalies of skin pigmentation (LC10‑LC1Y)..............................................1361 Hamartomata derived from dermal connective tissue (LC20‑LC2Y) ....................................1361 Developmental defects of hair or nails (LC30‑LC31).............................................................1361 Developmental anomalies of cutaneous vasculature (LC50‑LC5Z).......................................1361 Congenital anomalies of skin development (LC60‑LC60) .....................................................1362 Structural developmental anomalies of the adrenal glands (LC80‑LC8Z) ................................1362 Multiple developmental anomalies or syndromes (LD20‑LD2Z)..................................................1363 Chromosomal anomalies, excluding gene mutations (LD40‑LD7Z)..............................................1387 Sex chromosome anomalies (LD50‑LD5Z) ................................................................................1397 CHAPTER 21 ......................................................................................................................................1403 Symptoms, signs or clinical findings, not elsewhere classified.........................................................1403

ICD-11 MMS 17   
Symptoms, signs or clinical findings of blood, blood-forming organs, or the immune system  (MA00‑MA1Y) ...............................................................................................................................1404 

Symptoms or signs of blood, blood-forming organs, or the immune system (MA00‑MA0Y) ..1404 Clinical findings in blood, blood-forming organs, or the immune system (MA10‑MA1Y)........1404 

Symptoms, signs or clinical findings of endocrine, nutritional or metabolic diseases (MA50‑MA6Y) ......................................................................................................................................................1409 

Results of function studies of the endocrine, nutritional or metabolic diseases (MA50‑MA51) ..................................................................................................................................................1409 

Symptoms, signs or clinical findings of speech, language or voice (MA80‑MB0Y).......................1410 Symptoms or signs involving speech, language or voice (MA80‑MA8Y)..................................1410 Mental or behavioural symptoms, signs or clinical findings (MB20‑MB2Y).................................1412 Symptoms, signs or clinical findings of the nervous system (MB40‑MB9Y).................................1430 Symptoms or signs involving the nervous system (MB40‑MB6Y) ............................................1430 Paralytic symptoms (MB50‑MB5Z).......................................................................................1436 Clinical findings in the nervous system (MB70‑MB7Y).............................................................1439 Symptoms, signs or clinical findings of the visual system (MC10‑MC2Y).....................................1440 Symptoms or signs involving the visual system (MC10‑MC1Y) ................................................1440 Symptoms, signs or clinical findings of ear or mastoid process (MC40‑MC6Y)............................1441 Symptoms or signs involving the ear or mastoid process (MC40‑MC4Y).................................1441 Symptoms, signs or clinical findings of the circulatory system (MC80‑MC9Y).............................1442 Symptoms or signs involving the circulatory system (MC80‑MC8Y) ........................................1442 Symptoms, signs or clinical findings of the respiratory system (MD10‑MD6Y) ...........................1445 Symptoms or signs involving the respiratory system (MD10‑MD3Y).......................................1445 Haemorrhage from respiratory passages (MD20‑MD2Z).....................................................1447 Clinical findings in the respiratory system (MD40‑MD4Y)........................................................1450 Symptoms, signs or clinical findings of the digestive system or abdomen (MD80‑ME4Y)...........1451 Symptoms or signs involving the digestive system or abdomen (MD80‑ME1Y)......................1451 Symptoms related to the upper gastrointestinal tract (MD90‑MD9Y).................................1453 Symptoms related to the lower gastrointestinal tract or abdomen (ME00‑ME0Y) .............1454 Clinical findings in the digestive system (ME20‑ME2Y)............................................................1457 Symptoms, signs or clinical findings involving the skin (ME60‑ME6Y).........................................1461 Symptoms or signs involving the skin (ME60‑ME6Y)................................................................1461 Symptoms, signs or clinical findings of the musculoskeletal system (ME80‑MF1Y) ....................1467 Symptoms or signs of the musculoskeletal system (ME80‑ME8Y)...........................................1467 Clinical findings in the musculoskeletal system (ME90‑ME9Y).................................................1472

18 ICD-11 MMS    
Symptoms, signs or clinical findings of the genitourinary system (MF30‑MG0Y)........................1474 Symptoms, signs or clinical findings involving the female genital system (MF30‑MF3Y) ........1474 Symptoms, signs or clinical findings involving the male genital system (MF40‑MF4Y)............1475 Symptoms, signs or clinical findings involving the urinary system (MF50‑MF5Y)....................1476 Clinical findings in specimens from female genital organs (MF60‑MF6Z)................................1480 Clinical findings in specimens from male genital organs (MF70‑MF7Z)...................................1480 Clinical findings in specimens from the urinary system (MF80‑MF8Z).....................................1481 Clinical findings on examination of urine, without diagnosis (MF90‑MF9Y)............................1482 

General symptoms, signs or clinical findings (MG20‑MG7Z)........................................................1485 General symptoms (MG20‑MG4Y) ...........................................................................................1485 Pain (MG30‑MG3Z)...............................................................................................................1489 Finding of microorganism resistant to antimicrobial drugs (MG50‑MG5Z) .............................1507 

Clinical findings in specimens from other specified organs, systems and tissues (MG60‑MG6Y) ..................................................................................................................................................1522 

Abnormal results, not elsewhere classified (MG70‑MG7Z)......................................................1522 Ill-defined and unknown causes of mortality (MH10‑MH15).......................................................1523 CHAPTER 22 ......................................................................................................................................1525 Injury, poisoning or certain other consequences of external causes...............................................1525 Injuries to the head (NA00‑NA0Z) ................................................................................................1526 Injuries to the neck (NA20‑NA6Z).................................................................................................1541 Injury of nerves or spinal cord at neck level (NA30‑NA4Z).......................................................1544 Injury of spinal cord at neck level (NA30‑NA3Z)...................................................................1544 Injury of nerves at neck level (NA40‑NA4Z)..........................................................................1544 Injuries to the thorax (NA80‑NB3Z)..............................................................................................1547 Injury of nerves or spinal cord at thorax level (NA90‑NB2Z)....................................................1550 Injury of spinal cord at thorax level (NA90‑NA9Z)................................................................1550 Injury of nerves at thorax level (NB00‑NB0Y).......................................................................1550 Injuries to the abdomen, lower back, lumbar spine or pelvis (NB50‑NB9Z) ................................1556 Injury of nerves or lumbar spinal cord at abdomen, lower back or pelvis level (NB60‑NB7Z).1558 Injury of spinal cord at abdomen, lower back or pelvis level (NB60‑NB6Z) .........................1558 Injury of nerves at abdomen, lower back or pelvis level (NB70‑NB7Z)................................1559 Injuries to the shoulder or upper arm (NC10‑NC1Z) ....................................................................1569 Injuries to the elbow or forearm (NC30‑NC3Z).............................................................................1574 Injuries to the wrist or hand (NC50‑NC5Z) ...................................................................................1579

ICD-11 MMS 19   
Injuries to the hip or thigh (NC70‑NC7Z) ......................................................................................1589 Injuries to the knee or lower leg (NC90‑NC9Z).............................................................................1595 Injuries to the ankle or foot (ND10‑ND1Z)....................................................................................1602 Injuries involving multiple body regions (ND30‑ND37)................................................................1608 Injuries to unspecified part of trunk, limb or body region (ND50‑ND5Z).....................................1610 Effects of foreign body entering through natural orifice (ND70‑ND7Z).......................................1612 Burns (ND90‑NE2Z).......................................................................................................................1614 

Burns of external body surface, specified by site (ND90‑ND9Z)...............................................1614 Burns of eye or internal organs (NE00‑NE0Z)...........................................................................1618 Burns of multiple or unspecified body regions (NE10‑NE11)...................................................1618 

Frostbite (NE40‑NE4Z) ..................................................................................................................1619 Harmful effects of substances (NE60‑NE6Z).................................................................................1619 Injury or harm arising from surgical or medical care, not elsewhere classified (NE80‑NE8Z) .....1620 Other or unspecified effects of external causes (NF00‑NF0Z)......................................................1625 

CHAPTER 23 ......................................................................................................................................1631 External causes of morbidity or mortality ........................................................................................1631 Unintentional causes (PA00‑PB6Z) ...............................................................................................1631 Unintentional transport injury event (PA00‑PA5Z) ..................................................................1631 Unintentional land transport road traffic injury event (PA00‑PA0Z)....................................1632 Unintentional land transport off-road nontraffic injury event (PA10‑PA1Z)........................1633 

Unintentional land transport injury event unknown whether road traffic or off-road  nontraffic (PA20‑PA2Z) .........................................................................................................1634 

Unintentional railway transport injury event (PA30‑PA3Z)..................................................1635 Unintentional water transport injury event (PA40‑PA4Z)....................................................1635 Unintentional fall (PA60‑PA6Z).................................................................................................1636 Unintentional contact with person, animal or plant (PA70‑PA7Z)...........................................1636 Unintentional exposure to object, not elsewhere classified (PA80‑PA8Z)...............................1637 Unintentional immersion, submersion or falling into water (PA90‑PA9Z)...............................1637 Unintentional threat to breathing (PB00‑PB0Z) .......................................................................1638 Unintentional exposure to thermal mechanism (PB10‑PB1Z)..................................................1638 Unintentional exposure to or harmful effects of substances (PB20‑PB36)..............................1639 

Unintentional exposure to or harmful effects of drugs, medicaments or biological substances  (PB20‑PB29) ..........................................................................................................................1639 

Unintentional exposure to or harmful effects of substances chiefly nonmedicinal as to source  (PB30‑PB36) ..........................................................................................................................1640

20 ICD-11 MMS    
Unintentional exposure to other mechanism (PB50‑PB5B) .....................................................1640 Intentional self-harm (PB80‑PD3Z)...............................................................................................1641 Intentional self-harm by transport injury event (PB80‑PC2Z) ..................................................1641 Intentional self-harm by water transport injury event (PB90‑PB9Z)....................................1641 Intentional self-harm by air or space transport injury event (PC00‑PC0Z)...........................1642 Intentional self-harm by fall or jump (PC30‑PC3Z)...................................................................1642 Intentional self-harm by contact with person, animal or plant (PC40‑PC4Z)...........................1642 Intentional self-harm by exposure to object, not elsewhere classified (PC50‑PC5Z)...............1643 Intentional self-harm by immersion, submersion or falling into water (PC60‑PC6Z)...............1643 Intentional self-harm by threat to breathing (PC70‑PC7Z).......................................................1644 Intentional self-harm by exposure to thermal mechanism (PC80‑PC8Z) .................................1644 Intentional self-harm by exposure to or harmful effects of substances (PC90‑PD05).............1645 

Intentional self-harm by exposure to or harmful effects of drugs, medicaments or biological  substances (PC90‑PC99)........................................................................................................1645 

Intentional self-harm by exposure to or harmful effects of substances chiefly nonmedicinal as  to source (PD00‑PD05)..........................................................................................................1645 

Intentional self-harm by exposure to other mechanism (PD20‑PD29) ....................................1646 Assault (PD50‑PF2Z)......................................................................................................................1646 Assault by transport events (PD50‑PD9Z).................................................................................1646 Assault by water transport injury event (PD60‑PD6Z)..........................................................1647 Assault by air or space transport injury event (PD70‑PD7Z) ................................................1647 Assault by causing a fall or jump (PE00‑PE0Z)..........................................................................1647 Assault by contact with person, animal or plant (PE10‑PE1Z)..................................................1648 Assault by exposure to object not elsewhere classified (PE20‑PE4Z) ......................................1648 Assault by being cut or pierced by sharp object (PE30‑PE3Z) ..............................................1648 Assault by immersion, submersion or falling into water (PE50‑PE5Z) .....................................1649 Assault by threat to breathing (PE60‑PE6Z)..............................................................................1649 Assault by exposure to thermal mechanism (PE70‑PE7Z)........................................................1649 Assault by exposure to or harmful effects of substances (PE80‑PE95)....................................1650 

Assault by exposure to or harmful effects of drugs, medicaments or biological substances  (PE80‑PE8Z)...........................................................................................................................1650 

Assault by exposure to or harmful effects of substances chiefly nonmedicinal as to source  (PE90‑PE95)...........................................................................................................................1651 

Assault by exposure to other mechanism (PF10‑PF1B)............................................................1651 Undetermined intent (PF40‑PH8Z)...............................................................................................1652

ICD-11 MMS 21   
Transport injury event of undetermined intent (PF40‑PG4Z) ..................................................1652 Land transport road traffic injury event of undetermined intent (PF40‑PF4Z)....................1652 Land transport off-road nontraffic injury event of undetermined intent (PF50‑PF5Z)........1653 

Land transport injury event of undetermined intent, unknown whether road traffic or off road nontraffic (PF60‑PF6Z)..................................................................................................1654 

Railway transport injury event of undetermined intent (PF70‑PF7Z) ..................................1655 Water transport injury event of undetermined intent (PF80‑PG1Z)....................................1655 

Water transport injury event of undetermined intent with water vessel damaged, disabled  or destroyed (PF80‑PF8Z) .................................................................................................1655 

Water transport injury event of undetermined intent with water vessel not damaged,  disabled or destroyed (PF90‑PF9Z)...................................................................................1656 

Air or space transport injury event of undetermined intent (PG20‑PG2Z) ..........................1656 Fall or jump with undetermined intent (PG50‑PG5Z)...............................................................1656 Contact with person, animal or plant with undetermined intent (PG60‑PG6Z).......................1656 Contact with object, not elsewhere classified with undetermined intent (PG70‑PH0Z) .........1657 

Struck by projectile from firearm of undetermined intent (PG70‑PG7Z).............................1657 Cut or pierced by sharp object of undetermined intent (PG90‑PG9Z).................................1657 Immersion, submersion or falling into water with undetermined intent (PH10‑PH1Z)...........1658 Threat to breathing with undetermined intent (PH20‑PH2Z) ..................................................1658 Exposure to thermal mechanism with undetermined intent (PH30‑PH3Z)..............................1659 Exposure to or harmful effects of substances, undetermined intent (PH40‑PH56).................1659 

Exposure to or harmful effects of undetermined intent of drugs, medicaments or biological  substances (PH40‑PH49).......................................................................................................1659 

Exposure to or harmful effects of undetermined intent of substances chiefly nonmedicinal as  to source (PH50‑PH56)..........................................................................................................1660 

Exposure to other mechanism with undetermined intent (PH70‑PH7B).................................1660 Exposure to extreme forces of nature (PJ00‑PJ0Z).......................................................................1661 Maltreatment (PJ20‑PJ2Z) ............................................................................................................1662 Legal intervention (PJ40‑PJ4Z)......................................................................................................1662 Armed conflict (PJ60‑PK6Z)...........................................................................................................1663 

Explosion of marine weapons during armed conflict (PJ60‑PJ6Z)............................................1663 Attack on or destruction of aircraft during armed conflict (PJ70‑PJ7Z) ...................................1663 Other explosions or fragments during armed conflict (PJ80‑PJ8Z) ..........................................1663 Fires, conflagrations or hot substances during armed conflict (PJ90‑PJ9Z) .............................1664

22 ICD-11 MMS    
Firearm discharge or other forms of conventional warfare during armed conflict (PK00‑PK0Z) ..................................................................................................................................................1664 

Use of nuclear weapons during armed conflict (PK10‑PK1Z) ...................................................1664 Use of biological weapons during armed conflict (PK20‑PK2Z)................................................1664 

Chemical weapons or other forms of unconventional warfare during armed conflict (PK30‑PK3Z) ..................................................................................................................................................1665 

Harmful event occurring after cessation of armed conflict (PK40‑PK4Z).................................1665 Causes of healthcare related harm or injury (PK80‑PL14.Z).........................................................1665 

Surgical or other medical procedures associated with injury or harm in diagnostic or therapeutic  use (PK80‑PK8Z)........................................................................................................................1665 

Surgical or other medical devices, implants or grafts associated with injury or harm in  therapeutic use (PK90‑PK9C.4).................................................................................................1681 

Substances associated with injury or harm in therapeutic use (PL00‑PL0Z)............................1701 CHAPTER 24 ......................................................................................................................................1711 Factors influencing health status or contact with health services ...................................................1711 

Reasons for contact with the health services (QA00‑QD3Z) ........................................................1711 Contact with health services for purposes of examination or investigation (QA00‑QA0Z) .....1711 Contact with health services for counselling (QA10‑QA1Z)......................................................1718 Contact with health services for reasons associated with reproduction (QA20‑QA4Z)...........1720 

Contact with health services for procreative management (QA30‑QA3Z)...........................1720 

Health care related circumstances influencing the episode of care without injury or harm  (QA50‑QB0Z).............................................................................................................................1729 

Circumstances associated with a surgical or other medical procedure influencing the episode  of care, without injury or harm (QA50‑QA5Z)......................................................................1729 

Circumstances associated with a surgical or other medical device influencing the episode of  care without injury or harm (QA60‑QA6Z) ...........................................................................1730 

Circumstances associated with exposure to a drug, medicament or biological substance  influencing the episode of care without injury or harm (QA70‑QA7Z) ................................1731 

Circumstances associated with other aspects of care influencing the episode of care without  injury or harm (QA80‑QA8Z).................................................................................................1733 

Factors related to medical facilities or other health care (QB10‑QB1Z) ..................................1735 Donors of organs or tissues (QB20‑QB2Z) ................................................................................1736 Fitting, adjustment or management of devices (QB30‑QB3Z) .................................................1736 Dependence on enabling machines or devices (QB40‑QB4Z) ..................................................1738 Presence of device, implants or grafts (QB50‑QB5Z) ...............................................................1739 Surgical or postsurgical states (QB60‑QB6Z) ............................................................................1740

ICD-11 MMS 23   
Convalescence (QB70‑QB7Z) ....................................................................................................1742 Contact with health services for specific surgical interventions (QB80‑QB8Z) ........................1743 

Contact with health services for nonsurgical interventions not involving devices (QB90‑QB9Z) ..................................................................................................................................................1744 

Contact with health services related to immunizations or certain other prophylactic measures  (QC00‑QC0Z) .............................................................................................................................1746 

Interventions not carried out (QC10‑QC1Z) .............................................................................1749 Contact with health services associated with the health of others (QC20‑QC2Z) ...................1749 Personal or family history or late effect of prior health problems (QC40‑QC8Z).....................1750 

Personal history of health problems (QC40‑QC4Z) ..............................................................1750 Family history of health problems (QC60‑QC6Z)..................................................................1752 Risk factors associated with infectious or certain other conditions (QC90‑QD2Z) ..................1753 Carrier of infectious disease agent (QD00‑QD0Z).................................................................1754 Concern about body appearance (QD30‑QD3Z).......................................................................1754 Factors influencing health status (QD50‑QF2Z)............................................................................1755 Problems associated with finances (QD50‑QD5Z)....................................................................1755 Problems associated with drinking water or nutrition (QD60‑QD6Z) ......................................1755 Problems associated with the environment (QD70‑QD7Z)......................................................1755 Problems associated with employment or unemployment (QD80‑QD8Z)...............................1756 Problems associated with education (QD90‑QD9Z) .................................................................1757 Problems associated with social or cultural environment (QE00‑QE0Z)..................................1758 Problems associated with health behaviours (QE10‑QE2Z) .....................................................1759 Hazardous substance use (QE10‑QE1Z)................................................................................1759 Problems associated with social insurance or welfare (QE30‑QE3Z) .......................................1764 Problems associated with the justice system (QE40‑QE4Z) .....................................................1765 Problems associated with relationships (QE50‑QE5Z)..............................................................1765 Problems associated with absence, loss or death of others (QE60‑QE6Z)...............................1767 Problems associated with harmful or traumatic events (QE80‑QE8Z).....................................1768 Problems associated with upbringing (QE90‑QE9Z).................................................................1769 Acquired absence of body structure (QF00‑QF0Z)...................................................................1770 Difficulty or need for assistance with activities (QF20‑QF2Z)...................................................1771 CHAPTER 25 ......................................................................................................................................1773 Codes for special purposes...............................................................................................................1773 

International provisional assignment of new diseases of uncertain aetiology and emergency use  (RA00‑RA09)..................................................................................................................................1773

24 ICD-11 MMS    
National provisional assignment of new diseases of uncertain aetiology (RA20‑RA26)..............1774 CHAPTER 26 ......................................................................................................................................1776 Supplementary Chapter Traditional Medicine Conditions...............................................................1776 CHAPTER V ........................................................................................................................................1826 Supplementary section for functioning assessment.........................................................................1826 

WHODAS 2.0 36-item version.......................................................................................................1826 Cognition \[WHODAS\] ................................................................................................................1827 Mobility \[WHODAS\] ..................................................................................................................1827 Self-care \[WHODAS\]..................................................................................................................1828 Getting along \[WHODAS\]..........................................................................................................1828 Life activities \[WHODAS\]...........................................................................................................1829 Participation and impact of health problems \[WHODAS\].........................................................1830 

Brief Model Disability Survey........................................................................................................1830 Mental functions \[BMDS\]..........................................................................................................1831 Sensory functions and pain \[BMDS\]..........................................................................................1831 

Generic functioning domains........................................................................................................1831 Mental functions.......................................................................................................................1831 Sensory functions and pain.......................................................................................................1833 Voice and speech functions......................................................................................................1834 Functions of the cardiovascular, haematological, immunological and respiratory systems....1834 Functions of the digestive, metabolic and endocrine systems.................................................1834 Genitourinary and reproductive functions...............................................................................1835 Neuromusculoskeletal and movement-related functions........................................................1835 Functions of the skin and related structures............................................................................1836 Learning and applying knowledge ............................................................................................1836 General tasks and demands......................................................................................................1836 Communication.........................................................................................................................1837 Mobility.....................................................................................................................................1837 Self-care ....................................................................................................................................1838 Domestic life .............................................................................................................................1840 Interpersonal interactions and relationships............................................................................1841 Major life areas.........................................................................................................................1841 Community, social and civic life................................................................................................1842 CHAPTER X ........................................................................................................................................1843

ICD-11 MMS 25   
Extension Codes................................................................................................................................1843 Severity Scale Value ......................................................................................................................1844 Generic Severity Scale Value.....................................................................................................1844 Mild Moderate Severe Scale Value.......................................................................................1844 Clinical Staging Scale Value...................................................................................................1844 Grading Scale Value ..............................................................................................................1845 Phase Scale Value..................................................................................................................1845 Problem Scale Value .............................................................................................................1845 Disease Specific Severity Scale Value........................................................................................1846 Tumour spread simplified Scale Value..................................................................................1846 Tumour spread staging Scale Value......................................................................................1846 Histological Grading Scale Value...........................................................................................1846 NYHA Functional Classification: Class I-IV.............................................................................1847 Chronic Obstructive Lung Disease Criteria: GOLD 1-4 ..........................................................1847 Peripheral arterial disease (PAD) Severity Classification by Fontaine ..................................1847 Endometriosis Severity Scale Value ......................................................................................1847 Vocal Cord Paralysis Severity Scale Value.............................................................................1848 Sepsis Severity Scale Value ...................................................................................................1848 Peripheral arterial disease (PAD) Severity Classification by Rutherford ..............................1848 Pain Severity Scale Value ......................................................................................................1849 Pain intensity.....................................................................................................................1849 Pain-related distress .........................................................................................................1849 Pain-related interference..................................................................................................1850 Presence of psychosocial factors Scale Value.......................................................................1850 Adult Nutritional Status Scale Value.....................................................................................1850 Coronary atherosclerosis Severity Scale Value.....................................................................1851 Anaphylaxis Severity Scale Value..........................................................................................1851 Temporality...................................................................................................................................1851 Course of the Condition............................................................................................................1851 Pattern, Activity, or Clinical Status........................................................................................1851 Intermittent-Persistent Scale Value..................................................................................1851 Course ...................................................................................................................................1852 Acute-Subacute-Chronic Scale Value................................................................................1852 Onset.....................................................................................................................................1852

26 ICD-11 MMS    
Time in Life................................................................................................................................1852 Duration of pregnancy ..............................................................................................................1854 Aetiology .......................................................................................................................................1854 Causality....................................................................................................................................1854 Occupational relevance ........................................................................................................1854 Infectious Agents ......................................................................................................................1855 Other Pathogens...................................................................................................................1891 Topology Scale Value ....................................................................................................................1891 Relational ..................................................................................................................................1891 Distribution ...............................................................................................................................1891 Laterality ...................................................................................................................................1892 Regional.....................................................................................................................................1892 Anatomy and topography .............................................................................................................1892 Functional anatomy ..................................................................................................................1892 Haematopoietic system ........................................................................................................1892 Immune system.....................................................................................................................1893 Lymphoid organs...............................................................................................................1893 Endocrine system..................................................................................................................1898 Nervous system.....................................................................................................................1899 Nerve.................................................................................................................................1915 Number of Nerves.........................................................................................................1920 Visual system ........................................................................................................................1920 Auditory system....................................................................................................................1922 Circulatory system ................................................................................................................1924 Lymphatic system .............................................................................................................1948 Respiratory system................................................................................................................1951 Digestive system ...................................................................................................................1955 Integumentary system..........................................................................................................1963 Musculoskeletal system........................................................................................................1964 Bones.................................................................................................................................1964 Joints and ligaments..........................................................................................................1977 Number of joints...........................................................................................................1986 Number of Ligaments....................................................................................................1986 Cartilage ............................................................................................................................1987

ICD-11 MMS 27   
Muscles.............................................................................................................................1987 Tendons.............................................................................................................................1995 Genitourinary system............................................................................................................2002 Urinary system..................................................................................................................2002 Reproductive system.........................................................................................................2004 Surface topography...................................................................................................................2007 Partonomic view .......................................................................................................................2022 Walls in the Body ..................................................................................................................2022 Body Tissues..........................................................................................................................2023 Body Cavities.........................................................................................................................2024 Histopathology..............................................................................................................................2025 Acinar cell neoplasms ...............................................................................................................2025 Acinar cell neoplasms, benign...............................................................................................2025 Acinar cell neoplasms, malignant .........................................................................................2026 Acinar cell neoplasms, uncertain whether benign or malignant..........................................2026 Adenomas and adenocarcinomas.............................................................................................2026 Adenomas, benign ................................................................................................................2026 Adenocarcinomas in situ.......................................................................................................2030 Adenocarcinomas, malignant ...............................................................................................2031 Adenomas and adenocarcinomas, uncertain whether benign or malignant .......................2039 Adnexal and skin appendage neoplasms..................................................................................2040 Adnexal and skin appendage neoplasms, benign.................................................................2040 Adnexal and skin appendage neoplasms, in situ ..................................................................2041 Adnexal and skin appendage neoplasms, malignant............................................................2041 Adnexal and skin appendage neoplasms, uncertain whether benign or malignant ............2042 Basal cell neoplasms.................................................................................................................2042 Basal cell neoplasms, benign ................................................................................................2042 Basal cell neoplasms, malignant ...........................................................................................2042 Basal cell neoplasms, uncertain whether benign or malignant............................................2043 Blood vessel tumours................................................................................................................2044 Blood vessel tumours, benign...............................................................................................2044 Blood vessel tumours, malignant..........................................................................................2045 Blood vessel tumours, uncertain whether benign or malignant ..........................................2045 Complex epithelial neoplasms..................................................................................................2046

28 ICD-11 MMS    
Complex epithelial neoplasms, benign .................................................................................2046 Complex epithelial neoplasms, malignant............................................................................2046 Complex mixed and stromal neoplasms...................................................................................2046 Complex mixed and stromal neoplasms, benign..................................................................2046 Complex mixed and stromal neoplasms, malignant.............................................................2047 Complex mixed and stromal neoplasms, uncertain whether benign or malignant .............2049 Cystic, mucinous and serous neoplasms...................................................................................2049 Cystic, mucinous and serous neoplasms, benign..................................................................2049 Cystic, mucinous and serous neoplasms, in situ...................................................................2050 Cystic, mucinous and serous neoplasms, malignant ............................................................2051 Cystic, mucinous and serous neoplasms, uncertain whether benign or malignant.............2052 Ductal and lobular neoplasms ..................................................................................................2052 Ductal and lobular neoplasms, benign..................................................................................2052 Ductal and lobular neoplasms, in situ...................................................................................2053 Ductal and lobular neoplasms, malignant ............................................................................2054 Epithelial neoplasms, NOS ........................................................................................................2056 Epithelial neoplasms, benign ................................................................................................2056 Epithelial neoplasms, in situ .................................................................................................2056 Epithelial neoplasms, malignant...........................................................................................2056 Epithelial neoplasms, uncertain whether benign or malignant............................................2058 Fibroepithelial neoplasms.........................................................................................................2058 Fibroepithelial neoplasms, benign........................................................................................2058 Fibroepithelial neoplasms, malignant...................................................................................2059 Fibroepithelial neoplasms, uncertain whether benign or malignant ...................................2059 Fibromatous neoplasms............................................................................................................2059 Fibromatous neoplasms, benign...........................................................................................2059 Fibromatous neoplasms, malignant......................................................................................2061 Fibromatous neoplasms, uncertain whether benign or malignant......................................2062 Germ cell neoplasms.................................................................................................................2063 Germ cell neoplasms, benign................................................................................................2063 Germ cell neoplasms, in situ.................................................................................................2063 Germ cell neoplasms, malignant...........................................................................................2063 Germ cell neoplasms, uncertain whether benign or malignant ...........................................2064 Giant cell tumours.....................................................................................................................2065

ICD-11 MMS 29   
Giant cell tumours, benign....................................................................................................2065 Giant cell tumours, malignant...............................................................................................2065 Giant cell tumours, uncertain whether benign or malignant...............................................2065 

Gliomas .....................................................................................................................................2065 Gliomas, benign ....................................................................................................................2065 Gliomas, malignant ...............................................................................................................2065 Gliomas, uncertain whether benign or malignant................................................................2069 

Granular cell tumours and alveolar soft part sarcomas ...........................................................2069 Granular cell tumours and alveolar soft part sarcomas, benign ..........................................2069 Granular cell tumours and alveolar soft part sarcomas, malignant .....................................2070 

Lipomatous neoplasms.............................................................................................................2070 Lipomatous neoplasms, benign ............................................................................................2070 Lipomatous neoplasms, malignant.......................................................................................2070 Lipomatous neoplasms, uncertain whether benign or malignant........................................2071 

Lymphatic vessel tumours ........................................................................................................2071 Lymphatic vessel tumours, benign .......................................................................................2071 Lymphatic vessel tumours, malignant ..................................................................................2072 Lymphatic vessel tumours, uncertain whether benign or malignant...................................2072 

Meningiomas ............................................................................................................................2072 Meningiomas, benign ...........................................................................................................2072 Meningiomas, malignant ......................................................................................................2073 Meningiomas, uncertain whether benign or malignant.......................................................2073 

Mesonephromas.......................................................................................................................2073 Mesonephromas, benign ......................................................................................................2073 Mesonephromas, malignant.................................................................................................2073 Mesonephromas, uncertain whether benign or malignant .................................................2073 

Mesothelial neoplasms.............................................................................................................2074 Mesothelial neoplasms, benign ............................................................................................2074 Mesothelial neoplasms, malignant.......................................................................................2074 Mesothelial neoplasms, uncertain whether benign or malignant........................................2074 

Miscellaneous bone tumours....................................................................................................2074 Miscellaneous bone tumours, benign...................................................................................2074 Miscellaneous bone tumours, malignant .............................................................................2075 Miscellaneous tumours.............................................................................................................2075

30 ICD-11 MMS    
Miscellaneous tumours, benign............................................................................................2075 Miscellaneous tumours, malignant.......................................................................................2075 Miscellaneous tumours, uncertain whether benign or malignant .......................................2076 

Mucoepidermoid neoplasms....................................................................................................2076 Mucoepidermoid neoplasms, malignant..............................................................................2076 Mucoepidermoid neoplasms, uncertain whether benign or malignant...............................2076 

Myomatous neoplasms.............................................................................................................2076 Myomatous neoplasms, benign............................................................................................2076 Myomatous neoplasms, malignant.......................................................................................2077 Myomatous neoplasms, uncertain whether benign or malignant .......................................2078 

Myxomatous neoplasms...........................................................................................................2078 Myxomatous neoplasms, benign..........................................................................................2078 Myxomatous neoplasms, malignant.....................................................................................2078 

Nerve sheath tumours..............................................................................................................2079 Nerve sheath tumours, benign .............................................................................................2079 Nerve sheath tumours, malignant........................................................................................2080 Nerve sheath tumours, uncertain whether benign or malignant.........................................2080 

Neuroepitheliomatous neoplasms............................................................................................2080 Neuroepitheliomatous neoplasms, benign...........................................................................2080 Neuroepitheliomatous neoplasms, malignant .....................................................................2081 Neuroepitheliomatous neoplasms, uncertain whether benign or malignant......................2082 

Nevi and melanomas ................................................................................................................2082 Nevi and melanomas, benign................................................................................................2082 Nevi and melanomas, in situ.................................................................................................2084 Nevi and melanomas, malignant ..........................................................................................2084 Nevi and melanomas, uncertain whether benign or malignant...........................................2085 

Odontogenic tumours...............................................................................................................2085 Odontogenic tumours, benign..............................................................................................2085 Odontogenic tumours, malignant.........................................................................................2086 Odontogenic tumours, uncertain whether benign or malignant .........................................2087 

Osseous and chondromatous neoplasms.................................................................................2087 Osseous and chondromatous neoplasms, benign ................................................................2087 Osseous and chondromatous neoplasms, malignant...........................................................2088 Osseous and chondromatous neoplasms, uncertain whether benign or malignant............2089

ICD-11 MMS 31   
Paragangliomas and glomus tumours.......................................................................................2089 Paragangliomas and glomus tumours, benign......................................................................2089 Paragangliomas and glomus tumours, malignant ................................................................2089 Paragangliomas and glomus tumours, uncertain whether benign or malignant.................2090 

Soft tissue tumours and sarcomas, NOS...................................................................................2090 Soft tissue tumours and sarcomas, NOS, benign..................................................................2090 Soft tissue tumours and sarcomas, NOS, malignant.............................................................2091 Soft tissue tumours and sarcomas, NOS, uncertain whether benign or malignant .............2091 

Specialized gonadal neoplasms ................................................................................................2091 Specialized gonadal neoplasms, benign................................................................................2091 Specialized gonadal neoplasms, malignant ..........................................................................2092 Specialized gonadal neoplasms, uncertain whether benign or malignant...........................2092 

Squamous cell neoplasms.........................................................................................................2094 Squamous cell neoplasms, benign........................................................................................2094 Squamous cell neoplasms, in situ .........................................................................................2094 Squamous cell neoplasms, malignant...................................................................................2095 

Synovial-like neoplasms............................................................................................................2097 Synovial-like neoplasms, benign ...........................................................................................2097 Synovial-like neoplasms, malignant......................................................................................2097 

Thymic epithelial neoplasms.....................................................................................................2097 Thymic epithelial neoplasms, benign....................................................................................2097 Thymic epithelial neoplasms, malignant ..............................................................................2097 Thymic epithelial neoplasms, uncertain whether benign or malignant...............................2098 

Transitional cell papillomas and carcinomas............................................................................2098 Transitional cell papillomas and carcinomas, benign ...........................................................2098 Transitional cell papillomas and carcinomas, in situ ............................................................2099 Transitional cell papillomas and carcinomas, malignant......................................................2099 Transitional cell papillomas and carcinomas, uncertain whether benign or malignant.......2099 

Trophoblastic neoplasms..........................................................................................................2100 Trophoblastic neoplasms, benign .........................................................................................2100 Trophoblastic neoplasms, malignant....................................................................................2100 Trophoblastic neoplasms, uncertain whether benign or malignant.....................................2100 

Myelodysplastic syndromes......................................................................................................2100 Myelodysplastic syndromes, malignant................................................................................2100

32 ICD-11 MMS    
Other haematologic disorders..................................................................................................2101 Other haematologic disorders, malignant............................................................................2101 Other haematologic disorders, uncertain whether benign or malignant.............................2101 

Chronic myeloproliferative disorders.......................................................................................2101 Chronic myeloproliferative disorders, malignant.................................................................2101 Leukaemias ...............................................................................................................................2102 leukaemias, NOS, malignant.................................................................................................2102 Lymphoid leukaemias, malignant .........................................................................................2103 Myeloid leukaemias, malignant............................................................................................2104 Myeloid leukaemias, uncertain whether benign or malignant.............................................2106 Other leukaemias, malignant................................................................................................2106 Hodgkin and non-Hodgkin lymphomas.....................................................................................2106 Malignant lymphomas, NOS or diffuse.................................................................................2106 Hodgkin lymphoma...............................................................................................................2107 Non-Hodgkin lymphomas .....................................................................................................2109 Immunoproliferative diseases ..................................................................................................2113 Immunoproliferative diseases, malignant ............................................................................2113 Immunoproliferative diseases, uncertain whether benign or malignant.............................2113 Plasma cell tumours..................................................................................................................2114 Mast cell tumours.....................................................................................................................2114 Mast cell tumours, malignant...............................................................................................2114 Mast cell tumours, uncertain whether benign or malignant................................................2115 Neoplasms of histiocytes and accessory lymphoid cells...........................................................2115 Neoplasms of histiocytes and accessory lymphoid cells, malignant ....................................2115 

Neoplasms of histiocytes and accessory lymphoid cells, uncertain whether benign or  malignant ..............................................................................................................................2116 

Dimensions of injury .....................................................................................................................2116 Dimensions of Burns.................................................................................................................2116 Burns classified according to extent of body surface involved.............................................2116 Extent of body surface with full thickness or deep full thickness burn................................2117 Outcome of deep full thickness or complex burn.................................................................2117 Joint involvement in fracture....................................................................................................2118 Open fracture or closed fracture ..............................................................................................2118 Fracture types...........................................................................................................................2118

ICD-11 MMS 33   
Types of superficial injuries ......................................................................................................2119 Dimensions of external causes .....................................................................................................2120 Additional aspects of mechanism.............................................................................................2120 Exposure to other mechanism..............................................................................................2121 Activity when injured................................................................................................................2122 Sports, recreation or leisure activity.....................................................................................2123 Being taken care of ...............................................................................................................2123 Aspects of place of injury occurrence.......................................................................................2124 Type of place.........................................................................................................................2124 Part of place ..........................................................................................................................2127 Objects, living things or substances involved in causing injury ................................................2128 Land vehicle or means of land transport..............................................................................2128 Mobile machinery or special purpose vehicle ......................................................................2130 Watercraft or means of water transport..............................................................................2130 Aircraft or means of air transport.........................................................................................2131 Utensil or container ..............................................................................................................2136 Item mainly for personal use ................................................................................................2136 Equipment mainly used in sports or recreational activity ....................................................2139 Weapon.................................................................................................................................2142 Person, animal, plant or fungus............................................................................................2142 Building, building component, or related fitting ..................................................................2145 Ground surface or surface conformation .............................................................................2147 Material, not elsewhere classified........................................................................................2147 Food, drink ............................................................................................................................2149 Alcohol use in injury event........................................................................................................2150 Psychoactive drug use in injury event ......................................................................................2151 Aspects of transport injury events............................................................................................2151 Mode of transport of person injured in transport event......................................................2151 Vehicle user role of person injured in transport event.........................................................2157 Counterpart in land transport crash .....................................................................................2158 Other mechanisms of transport injury without counterpart................................................2163 Aspects of sports injury events.................................................................................................2163 Type of sport or exercise activity..........................................................................................2163 Phase of sport or exercise activity ........................................................................................2171

34 ICD-11 MMS    
Personal countermeasures in sport or exercise ...................................................................2172 Environmental countermeasures in sport or exercise..........................................................2172 Aspects of occupational injury events......................................................................................2173 Economic activity ..................................................................................................................2173 Occupation............................................................................................................................2174 Aspects of assault and maltreatment.......................................................................................2174 Perpetrator-victim relationship ............................................................................................2174 Gender of perpetrator ..........................................................................................................2176 Context of assault and maltreatment...................................................................................2176 Aspects of intentional self-harm events...................................................................................2178 Proximal risk-factors for intentional self-harm.....................................................................2178 Previous non-fatal intentional self harm ..............................................................................2179 Intention to die aspect of self-harm .....................................................................................2180 Aspects of armed conflict .........................................................................................................2180 Type of armed conflict..........................................................................................................2180 Role of injured person in armed conflict ..............................................................................2180 Type of legal intervention.........................................................................................................2180 Aspects of incidents related to devices ....................................................................................2181 Investigation conclusion of events related to devices..............................................................2216 Findings of investigations related to devices............................................................................2216 Cause investigation and type of investigation..........................................................................2227 Medical device component.......................................................................................................2230 Biological and chemical medical device component ............................................................2230 Electrical and magnetic medical device component ............................................................2231 Measurement medical device component...........................................................................2236 Mechanical medical device component ...............................................................................2238 Optical medical device component ......................................................................................2249 Safety medical device component........................................................................................2250 Other component of medical device ....................................................................................2251 Consciousness...............................................................................................................................2251 Glasgow Coma Scale Eye opening score...................................................................................2251 Glasgow Coma Scale Motor score ............................................................................................2252 Glasgow Coma Scale Verbal score ............................................................................................2252 Pupil reaction score ..................................................................................................................2252

ICD-11 MMS 35   
Substances....................................................................................................................................2253 Medicaments ............................................................................................................................2253 Agents primarily affecting the gastrointestinal system........................................................2253 Gastric acid secretion suppressants..................................................................................2253 Histamine H2-receptor antagonists..............................................................................2253 Other drugs for peptic ulcer and gastro-oesophageal reflux disease...............................2254 Drugs for functional gastrointestinal disorders................................................................2255 Antidiarrhoeal drugs.........................................................................................................2256 Digestants .........................................................................................................................2257 Antinauseants, antiemetics and emetics..........................................................................2258 Other agents primarily affecting gastrointestinal system ................................................2258 Other antacids and anti-gastric-secretion drugs ..............................................................2259 Other laxatives..................................................................................................................2260 Saline and osmotic laxatives.............................................................................................2261 Drugs for constipation ......................................................................................................2262 Laxatives........................................................................................................................2262 Propulsives........................................................................................................................2264 Antipropulsives.................................................................................................................2265 Agents primarily affecting blood constituents and immune system....................................2265 Antineoplastic agents........................................................................................................2265 Antineoplastic antimetabolites.....................................................................................2266 Antineoplastic natural products and derivatives..........................................................2267 Monoclonal antibodies.................................................................................................2268 Other antineoplastic drugs ...........................................................................................2270 Immunostimulants............................................................................................................2277 Immunosuppressive agents..............................................................................................2279 Anticoagulants and antithrombotics ................................................................................2282 Platelet aggregation inhibitors......................................................................................2282 Other fibrinolysis-affecting drugs .....................................................................................2285 Anticoagulant antagonists, vitamin K and other coagulants............................................2285 Natural blood and blood products....................................................................................2286 Iron and its compounds....................................................................................................2288 Vitamin B12, folic acid and other anti-megaloblastic-anaemia preparations..................2290 Enzymes ............................................................................................................................2290

36 ICD-11 MMS    
Drugs used in hereditary angioedema..............................................................................2291 Local hemostatics..............................................................................................................2291 Other haematological agents............................................................................................2292 

Agents affecting genitourinary system, sex and anabolic hormones...................................2292 Other gynaecologicals.......................................................................................................2292 Intrauterine and intravaginal contraceptives...................................................................2292 Estrogens and progestogens.............................................................................................2292 Estrogen receptor modulators..........................................................................................2295 Progesterone receptor modulators..................................................................................2296 Androgens and anabolic congeners..................................................................................2296 Other urologicals...............................................................................................................2297 Drugs used in benign prostatic hypertrophy ....................................................................2298 

Hormones and their synthetic substitutes and antagonists, not elsewhere classified ........2298 Anterior pituitary \[adenohypophyseal\] hormones and analogues...................................2298 Posterior pituitary hormones and analogues...................................................................2299 Hypothalamic hormones and analogues ..........................................................................2300 

Gonadotropin releasing hormones and analogues.......................................................2300 Prolactin inhibitors............................................................................................................2301 Glucocorticoids and synthetic analogues .........................................................................2301 Anticorticosteroids............................................................................................................2302 Antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified ................2302 Thyroid hormones and substitutes...................................................................................2304 Antithyroid drugs..............................................................................................................2304 Iodine therapy...................................................................................................................2305 Parathyroid hormones and analogues..............................................................................2305 Antiparathyroid agents.....................................................................................................2305 Insulin and antidiabetic drugs...........................................................................................2305 

Sulfonamides (heterocyclic)..........................................................................................2307 Agents affecting bones, joints and other connective tissue, not elsewhere classified ........2310 Bisphosphonates...............................................................................................................2310 Bone morphogenetic proteins..........................................................................................2310 Enzymes affecting bones, joints and other connective tissue, not elsewhere classified .2310 Agents primarily affecting water and nutrition-balance and metabolism ...........................2311 Drugs affecting uric acid metabolism and other antigout preparations ..........................2311

ICD-11 MMS 37   
Mineral salts and supplements, not elsewhere classified ................................................2312 Electrolytic, caloric and water-balance agents.................................................................2315 Diuretics............................................................................................................................2317 

Loop \[high-ceiling\] diuretics..........................................................................................2319 Mineralocorticoids............................................................................................................2320 Vitamins and antioxidants ................................................................................................2320 Enzymes and digestants....................................................................................................2322 Agents in bile and liver therapy ........................................................................................2323 Antiobesity preparations ..................................................................................................2324 

Drugs used to treat enzyme deficiencies and disorders of aminoacid, glycolipid and  glycoprotein metabolism..................................................................................................2325 

Agents primarily affecting the cardiovascular system..........................................................2326 Agents acting on the renin-angiotensin system ...............................................................2326 Antihyperlipidemic and antiarteriosclerotic drugs...........................................................2327 Calcium-channel blockers.................................................................................................2330 Cardiac stimulants.............................................................................................................2331 

Predominantly beta-adrenoreceptor agonists .............................................................2332 Antiarrhythmics ................................................................................................................2335 Other antihypertensive drugs...........................................................................................2336 Vasodilators used in cardiac diseases...............................................................................2339 Peripheral vasodilators.....................................................................................................2341 Other agents primarily affecting the cardiovascular system............................................2343 Vasoprotectives ................................................................................................................2344 

Agents used in antivaricose therapy.............................................................................2345 Drugs primarily affecting the autonomic nervous system....................................................2345 Adrenergic agonists...........................................................................................................2345 Adrenergic antagonists.....................................................................................................2347 Alpha-adrenoreceptor antagonists...............................................................................2347 Beta-adrenoreceptor antagonists.................................................................................2347 Parasympatholytics \[anticholinergics and antimuscarinics\] and spasmolytics ................2349 Parasympathomimetics \[cholinergics\]..............................................................................2355 Anticholinesterase agents.............................................................................................2355 Ganglionic blocking drugs.................................................................................................2356 Drugs used in addictive disorders.........................................................................................2357

38 ICD-11 MMS    
Antivertigo and motion sickness preparations.....................................................................2357 Agents primarily acting on smooth and skeletal muscles and the respiratory system ........2357 Oxytocic drugs...................................................................................................................2357 Muscle relaxants...............................................................................................................2358 Other drugs acting on muscles .........................................................................................2360 Botulinum toxin derivatives..........................................................................................2360 Expectorants and mucolytics............................................................................................2362 Antitussives.......................................................................................................................2364 Respiratory stimulants......................................................................................................2368 Systemic antibiotics, anti-infectives and antiparasitics........................................................2369 Systemic antibiotics and antibacterials.............................................................................2369 Penicillins ......................................................................................................................2369 Cephalosporins and other beta-lactam antibiotics.......................................................2371 Macrolides.....................................................................................................................2375 Aminoglycosides ...........................................................................................................2376 Other antibacterials......................................................................................................2379 Tetracyclines.................................................................................................................2380 Antimycobacterials ...........................................................................................................2380 Antifungal agents..............................................................................................................2383 Antiviral drugs...................................................................................................................2383 Antivenin, antivenom (sera), Immunoglobulin.................................................................2388 Vaccines ............................................................................................................................2390 Other specified systemic anti-infectives and antiparasitics..............................................2406 Antiprotozoal drugs ..........................................................................................................2406 Antimalarials and drugs acting on other blood protozoa .............................................2406 Other agents against amoebiasis and other protozoal diseases..................................2409 Anthelminthics..................................................................................................................2411 Neuroprotective agents, not elsewhere classified ...............................................................2413 Analgesics, antipyretics and anti-inflammatory drugs..........................................................2414 Specific antirheumatic agents...........................................................................................2417 Acetylsalicylic acid and other salicylates ..........................................................................2417 Pyrazolone derivatives......................................................................................................2418 Paracetamol (acetaminophen) and 4-aminophenol derivatives......................................2419 Other nonopioid analgesics and antipyretics, not elsewhere classified...........................2419

ICD-11 MMS 39   
Antiepileptics and antiparkinsonism drugs...........................................................................2421 Antipsychotics \[neuroleptics\] ...............................................................................................2424 Phenothiazine antipsychotics and neuroleptics...............................................................2424 Butyrophenone derivatives...............................................................................................2426 Lithium ..............................................................................................................................2427 Other antipsychotics and neuroleptics.............................................................................2427 Antidepressants....................................................................................................................2428 Monoamine oxidase-inhibitor, non-selective...................................................................2428 Selective serotonin reuptake inhibitors............................................................................2429 Serotonin-norepinephrine reuptake inhibitors ................................................................2429 Other antidepressants......................................................................................................2430 Cannabinoids & hallucinogens..............................................................................................2432 Other psychodysleptics \[hallucinogens\] ...........................................................................2434 Synthetic cannabinoids.....................................................................................................2435 Unspecified psychodysleptics \[hallucinogens\]..................................................................2435 Opioids..................................................................................................................................2435 Opioids or related analgesics and agents affecting opioid receptors...............................2435 Opioid receptor antagonists .........................................................................................2437 Psychostimulants..................................................................................................................2440 Cathinone..........................................................................................................................2440 Other specified amphetamines.........................................................................................2440 Unspecified psychostimulant drug ...................................................................................2440 Sedative hypnotic drugs and other central nervous system depressants............................2440 Anaesthetics and therapeutic gases.................................................................................2440 General anaesthetics ....................................................................................................2440 Sedative-hypnotic and anxiolytic drugs............................................................................2446 Benzodiazepines ...........................................................................................................2446 Bromine compounds.....................................................................................................2450 Other sedatives, hypnotics and antianxiety drugs........................................................2450 Other and unspecified drugs, medicaments and biological substances...............................2454 Antidotes...........................................................................................................................2454 Iron chelating agents.........................................................................................................2456 Drugs for treatment of hyperkalaemia, hypercalcaemia and hyperphosphataemia .......2456 Detoxifying agents for antineoplastic treatment..............................................................2456

40 ICD-11 MMS    
Protectives against UV-radiation for systemic use ...........................................................2457 Antipsoriatics for systemic use .........................................................................................2457 Vitamin A derivative and other anti-acne preparations for systemic use ........................2457 Agents used in diagnostic tests, not elsewhere classified................................................2457 

Tests for bile duct patency............................................................................................2458 Tests for pituitary function ...........................................................................................2458 Medical gases....................................................................................................................2460 Contrast media..................................................................................................................2460 X-ray contrast media, non-iodinated............................................................................2461 

Topical agents primarily affecting skin and mucous membrane and ophthalmological,  otorhinolaryngological and dental drugs..............................................................................2465 

Antipruritics ......................................................................................................................2465 Camphor............................................................................................................................2465 Emollients, demulcents and protectants..........................................................................2465 Fluoride preparations .......................................................................................................2468 Iodine (antiseptic).............................................................................................................2468 Keratolytics, keratoplastics, and other hair treatment drugs and preparations..............2468 Ophthalmological drugs and preparations.......................................................................2470 Other dental drugs, topically applied ...............................................................................2474 Other local antifungal, anti-infective and anti-inflammatory drugs.................................2474 Other local astringents and local detergents....................................................................2484 Other topical agents..........................................................................................................2485 Otorhinolaryngological drugs and preparations...............................................................2488 Topical corticosteroid preparations..................................................................................2489 Retinoids topical ...............................................................................................................2490 

Substances, chiefly nonmedicinal.............................................................................................2491 Animal toxin, venom, or poison............................................................................................2501 Corrosive substance..............................................................................................................2509 Explosive chemical ................................................................................................................2512 Gas, fumes or vapour............................................................................................................2513 Halogen derivative of aliphatic and aromatic hydrocarbons................................................2516 Inorganic substance ..............................................................................................................2519 Metal.....................................................................................................................................2520 Organic solvent .....................................................................................................................2524

ICD-11 MMS 41   
Paint or dye...........................................................................................................................2530 Substance of plant origin ......................................................................................................2532 Substance of human origin ...................................................................................................2543 Adhesive, not elsewhere classified.......................................................................................2543 Chemical compounds not elsewhere classified....................................................................2543 Chemicals used as process regulators ..................................................................................2543 Cleaning agent, not elsewhere classified..............................................................................2544 Food additives not elsewhere classified ...............................................................................2544 Organic compounds not elsewhere classified ......................................................................2544 Preservative nonmedicinal, not elsewhere classified...........................................................2545 Substance eaten as food, nonbacterial, not elsewhere classified........................................2545 Synthetic fragrances not elsewhere classified......................................................................2547 

Diagnosis code descriptors...........................................................................................................2548 Discharge diagnosis types.........................................................................................................2548 Diagnosis timing........................................................................................................................2548 Diagnosis timing in relation to surgical procedure ...................................................................2548 Diagnosis method of confirmation ...........................................................................................2548 Diagnosis certainty....................................................................................................................2548 Obstetrical diagnosis timing......................................................................................................2549 Encounter descriptors...............................................................................................................2549 

Capacity or context.......................................................................................................................2549 Biological sex.............................................................................................................................2549 Health Devices, Equipment and Supplies .....................................................................................2549 Devices for administration, collecting and picking ...................................................................2549 Hematology and hemotransfusion devices..............................................................................2549 Cardiocirculatory devices..........................................................................................................2549 Disinfectants, antiseptics and proteolytics for medical devices...............................................2550 Dialysis devices..........................................................................................................................2550 Gastrointestinal devices............................................................................................................2553 Suture devices...........................................................................................................................2553 Active-implantable devices.......................................................................................................2553 Endotherapy and electrosurgical devices.................................................................................2553 Reusable surgical instruments..................................................................................................2553 Devices for generic and specialistic medication .......................................................................2553

42 ICD-11 MMS    
Devices for nervous and medullary systems ............................................................................2553 Implantable prosthetic devices and osteosynthesis devices....................................................2553 Dental, ophthalmologic and ear, nose and throat devices.......................................................2553 Respiratory and anaesthesia devices........................................................................................2553 Sterilization devices ..................................................................................................................2554 Protection devices and incontinence aids................................................................................2554 Medical devices, urogenital apparatus.....................................................................................2554 Medical devices \- various..........................................................................................................2554 In vitro diagnostic devices.........................................................................................................2554 Supports or technical aids for disabled persons.......................................................................2555 Medical equipment and related accessories and materials.....................................................2555

ICD-11 MMS 43   
**CHAPTER 01** 

**Certain infectious or parasitic diseases** 

This chapter has 344 four-character categories. 

Code range starts with 1A00 

This chapter includes certain conditions caused by pathogenic organisms or microorganisms, such as  bacteria, viruses, parasites or fungi. 

***Exclusions:*** Infection arising from device, implant or graft, not elsewhere classified (NE83.1) ***Coded Elsewhere:*** Infections of the fetus or newborn (KA60-KA6Z) 

Human prion diseases (8E00-8E0Z) 

Pneumonia (CA40) 

This chapter contains the following top level blocks: 

• Gastroenteritis or colitis of infectious origin 

• Predominantly sexually transmitted infections 

• Mycobacterial diseases 

• Certain staphylococcal or streptococcal diseases 

• Pyogenic bacterial infections of the skin or subcutaneous tissues 

• Certain zoonotic bacterial diseases 

• Other bacterial diseases 

• Human immunodeficiency virus disease 

• Viral infections of the central nervous system 

• Non-viral and unspecified infections of the central nervous system 

• Dengue 

• Certain arthropod-borne viral fevers 

• Certain zoonotic viral diseases 

• Certain other viral diseases 

• Influenza 

• Viral hepatitis 

• Viral infections characterised by skin or mucous membrane lesions 

• Mycoses 

• Parasitic diseases 

• Sepsis 

• Sequelae of infectious diseases

44 ICD-11 MMS    
Gastroenteritis or colitis of infectious origin (1A00‑1A40.Z) 

***Coded Elsewhere:*** Intestinal fungal infections 

Bacterial intestinal infections (1A00‑1A0Z) 

Any condition of the intestines, caused by an infection with a bacterial source. 

***Exclusions:*** Bacterial foodborne intoxications (1A10‑1A1Z) 

Helicobacter pylori induced gastritis (DA42.1) 

Helicobacter pylori associated gastric ulcer (DA60.1) 

Helicobacter-pylori associated duodenitis (DA51.0) 

Helicobacter-pylori associated duodenal ulcer (DA63.1) 

Helicobacter pylori associated and drug-induced gastric ulcer (DA60.2) 

Helicobacter-pylori associated and drug-induced duodenal ulcer (DA63.2) 

***Coded Elsewhere:*** Abdominal actinomycosis (1C10.1) 

Listerial gastroenteritis (1C1A.Y) 

 1A00 **Cholera** 

Cholera is a potentially epidemic and life-threatening infection of the intestine,  characterised by extreme watery (secretory) diarrhoea often accompanied by  vomiting, with rapid depletion of body fluids and salt that may result in hypovolemic  shock and acidosis. Cholera outbreaks are caused by toxigenic strains of Vibrio  cholerae serogroups O1 and O139. Serogroup O1 has two biovars; classical and  eltor. Vibrio cholerae O1, biovar cholerae is classical type. Vibrio cholerae O1,  biovar eltor is eltor type. 

***Inclusions:*** cholera syndrome 

 1A01 **Intestinal infection due to other Vibrio** 

 1A02 **Intestinal infections due to Shigella** 

A disease caused by an infection with the gram-negative bacteria genus Shigella.  This disease is characterised by an acute onset of small volume diarrhoea,  accompanied by fever and nausea. This disease may also present with toxaemia,  vomiting, cramps, and tenesmus. Transmission is by ingestion of contaminated  food, or direct contact. Confirmation is by identification of Shigella in a faecal  sample. 

 1A03 **Intestinal infections due to Escherichia coli** 

Any condition of the gastrointestinal system, caused by an infection with the gram negative bacteria Escherichia coli. 

**1A03.0 Enteropathogenic Escherichia coli infection** 

An infection of the gastrointestinal system, caused by the gram-negative bacteria  Escherichia coli. It is characterised by acute, profuse, watery diarrhoea.  Transmission is by the faecal-oral route from contaminated food, water, or fomites.  Confirmation is by identification of enteropathogenic Escherichia coli (EPEC) in a  faecal sample.

ICD-11 MMS 45   
**1A03.1 Enterotoxigenic Escherichia coli infection** 

A condition of the gastrointestinal system, caused by an infection with the gram negative bacteria Escherichia coli. This condition is characterised by acute, watery  diarrhoea due to toxins released from the bacteria. Transmission is by the faecal oral route from ingestion of contaminated food, water, or fomites. Confirmation is by  identification of enterotoxigenic Escherichia coli (ETEC) in faecal sample. 

**1A03.2 Enteroinvasive Escherichia coli infection** 

A condition of the gastrointestinal system, caused by an infection with the gram negative bacteria Escherichia coli. This condition is characterised by acute and  profuse diarrhoea (that may be haemorrhagic), fever, and abdominal cramps.  Transmission is by the faecal-oral route from ingestion of contaminated food or  water. Confirmation is by identification of enteroinvasive Escherichia coli (EIEC) in a  faecal sample. 

**1A03.3 Enterohaemorrhagic Escherichia coli infection** 

**1A03.Y Intestinal infections due to other specified Escherichia coli 1A03.Z Intestinal infections due to Escherichia coli, unspecified** 

 1A04 **Intestinal infections due to Clostridioides difficile** 

A disease of the colon, caused by an infection with toxigenic strains of the gram positive bacteria Clostridioides difficile (formerly known as Clostridium difficile). This  disease is characterised by colitis, diarrhoea, abdominal pain, and fever.  Transmission is commonly by direct or indirect contact. A disturbance of the normal  bacterial flora of the colon, e.g. due to antibiotic treatment, facilitates the  development of an intestinal infection with Clostridioides difficile. Confirmation is by  identification of Clostridioides difficile in a faecal sample. 

***Exclusions:*** Necrotising enterocolitis of newborn (KB88) 

 1A05 **Intestinal infections due to Yersinia enterocolitica** 

A disease of the intestinal tract, caused by an infection with the gram-negative  bacteria Yersinia enterocolitica. This disease commonly presents with a fever,  diarrhoea, or abdominal pain. This disease may also lead to a systemic infection.  Transmission is by the faecal-oral route from the ingestion of contaminated food or  water, or direct contact with infected individuals or animal. Confirmation is by  identification of Yersinia enterocolitica in a faecal sample. 

***Exclusions:*** Extraintestinal yersiniosis (1B9A) 

***Coded Elsewhere:*** Postinfectious arthropathy in enteritis due to Yersinia    
enterocolitica (1A05) 

 1A06 **Gastroenteritis due to Campylobacter** 

 1A07 **Typhoid fever** 

A condition caused by an infection with the gram-negative bacteria Salmonella  typhi. This condition is characterised by an acute sustained fever. This condition  may present with weakness, stomach pains, headache, loss of appetite, or flat,  rose-coloured spots. Transmission is by the faecal-oral route from the ingestion of  contaminated food or water. Confirmation is by identification of Salmonella typhi in a  faecal or blood sample.

46 ICD-11 MMS    
**1A07.0 Typhoid peritonitis** 

**1A07.Y Other specified typhoid fever** 

**1A07.Z Typhoid fever, unspecified** 

 1A08 **Paratyphoid fever** 

A condition caused by an infection with the gram-negative bacteria Salmonella  paratyphi. This condition is characterised by an acute sustained fever. The  individual may feel weak, have stomach pains, headache, loss of appetite, or a rash  of flat, rose-coloured spots. Transmission is by ingestion of contaminated food or  water. Confirmation is by identification of Salmonella paratyphi in a faecal or blood  sample. 

 1A09 **Infections due to other Salmonella** 

***Coding Note:*** Infection or foodborne intoxication due to any Salmonella species other than S.  typhi and S. paratyphi 

**1A09.0 Salmonella enteritis** 

This refers to inflammation of the small intestine due to infection with bacteria of the  genus Salmonella, a member of the family Enterobacteriaceae. Bacteria of the  genus Salmonella are rod-shaped, Gram-negative, non-spore-forming and  predominantly motile. 

**1A09.Y Infections due to other Salmonella in other organs** 

***Coding Note:*** Infection or foodborne intoxication due to any Salmonella species other than S.  typhi and S. paratyphi 

**1A09.Z Salmonella infection, unspecified** 

***Coding Note:*** Infection or foodborne intoxication due to any Salmonella species other than S.  typhi and S. paratyphi 

 1A0Y **Other specified bacterial intestinal infections** 

 1A0Z **Bacterial intestinal infections, unspecified** 

Bacterial foodborne intoxications (1A10‑1A1Z) 

Any condition caused by an intoxication due to a bacterial toxin. Intoxication is by ingestion of  contaminated food. 

***Exclusions:*** salmonella foodborne intoxication and infection (1A09) 

Listeriosis (1C1A) 

Harmful effects of or exposure to noxious substances, Substances chiefly    
nonmedicinal as to source, Other noxious substances eaten as food    
(NE61) 

Ichthyotoxism not specified as bacterial (NE61) 

 1A10 **Foodborne staphylococcal intoxication**

ICD-11 MMS 47   
 1A11 **Botulism** 

A disease caused by an infection with the gram-positive bacteria Clostridium  botulinum. This disease commonly presents with abdominal pain, vomiting, acute  paralysis, blurred vision, diplopia, and may be fatal. Transmission is by ingestion of  contaminated food, direct contact, or from accidental overdose. Confirmation is by  identification of Clostridium botulinum in a faecal or food sample. 

**1A11.0 Foodborne intoxication by botulinum toxin** 

**1A11.1 Other forms of botulism** 

**1A11.Z Botulism, unspecified** 

 1A12 **Foodborne Clostridium perfringens intoxication** 

***Inclusions:*** enteritis necroticans 

foodborne Clostridium welchii intoxication 

 1A13 **Foodborne Bacillus cereus intoxication** 

 1A1Y **Other specified bacterial foodborne intoxications** 

 1A1Z **Bacterial foodborne intoxications, unspecified** 

Viral intestinal infections (1A20‑1A2Z) 

Any condition of the intestines, caused by an infection with a viral source. 

***Exclusions:*** influenza with involvement of gastrointestinal tract (1E32) ***Coded Elsewhere:*** Herpes simplex virus duodenitis (1F00.Y) 

Human immunodeficiency virus disease enteritis (1C62.2) 

 1A20 **Enteritis due to Adenovirus** 

A disease of the intestinal tract, caused by an infection with adenovirus. This  disease is characterised by a fever, diarrhoea, or vomiting. Transmission is by the  faecal-oral route. 

 1A21 **Gastroenteritis due to Astrovirus** 

 1A22 **Gastroenteritis due to Rotavirus** 

A disease of the gastrointestinal tract, caused by an infection with rotavirus. This  disease is characterised by acute onset of vomiting, non-haemorrhagic diarrhoea,  and abdominal pain. Transmission is by ingestion of contaminated food or water,  direct contact, or through fomites. Confirmation is by identification of rotavirus. 

 1A23 **Enteritis due to Norovirus** 

A disease of the gastrointestinal tract, caused by an infection with norovirus. This  disease is characterised by acute onset of vomiting, non-haemorrhagic diarrhoea,  and abdominal pain. Transmission is by ingestion of contaminated food or water,  direct contact, or through fomites. Confirmation is by identification of norovirus.

48 ICD-11 MMS    
 1A24 **Intestinal infections due to Cytomegalovirus** 

A condition of the intestinal tract, caused by an infection with cytomegalovirus. The  condition is characterised by diarrhoea, fever, abdominal pain, or haematochezia.  Transmission is by direct contact with infected body fluids. 

 1A2Y **Other specified viral intestinal infections** 

 1A2Z **Viral intestinal infections, unspecified** 

Protozoal intestinal infections (1A30‑1A3Z) 

Any condition of the intestines, caused by an infection with a protozoal parasitic source. 

 1A30 **Infections due to Balantidium coli** 

Any condition caused by an infection with the protozoan parasite Balantidium coli. 

 1A31 **Giardiasis** 

A condition caused by an infection with the protozoan parasite Giardia. This  condition is characterised by gastroenteritis, or may be asymptomatic. Transmission  is by the faecal-oral route from the ingestion of contaminated food or water.  Confirmation is by identification of Giardia in a faecal sample. 

 1A32 **Cryptosporidiosis** 

Any condition caused by an infection with the protozoan parasite Cryptosporidium. 

 1A33 **Cystoisosporiasis** 

A disease caused by the protozoan parasite Cystoisospora belli. This disease is  characterised by watery diarrhoea, fever, abdominal pain, nausea, or malaise.  Transmission is by the faecal-oral route, commonly through the ingestion of  contaminated food or water. Confirmation is by identification of Cystoisospora belli  in a faecal sample. 

**1A33.0 Cystoisosporiasis of small intestine** 

***Inclusions:*** Infection due to Isopora belli 

Infection due to Isopora hominis 

**1A33.1 Cystoisosporiasis of colon** 

Isosporiasis of colon is a large intestinal inflammation caused by the protozoan  Isospora belli. 

**1A33.Y Other specified cystoisosporiasis** 

**1A33.Z Cystoisosporiasis, unspecified** 

 1A34 **Sarcocystosis** 

Any condition caused by an infection with the protozoan parasite Sarcocystis. ***Inclusions:*** Sarcosporidiosis 

 1A35 **Blastocystosis**

ICD-11 MMS 49   
 1A36 **Amoebiasis** 

***Inclusions:*** infection due to Entamoeba histolytica 

**1A36.0 Intestinal infections due to Entamoeba** 

**1A36.00** Acute amoebiasis 

A disease caused by an infection with the protozoan parasite Entamoeba  histolytica. This disease is characterised by fever, abdominal pain, tenesmus, or  diarrhoea containing blood. Transmission is by the faecal-oral route or ingestion of  contaminated food or water. Confirmation is by identification of Entamoeba  histolytica in a faecal or blood sample. 

***Inclusions:*** amoebic dysentery 

**1A36.01** Amoeboma of intestine 

**1A36.0Y** Other specified intestinal infections due to Entamoeba 

**1A36.0Z** Intestinal infections due to Entamoeba, unspecified 

**1A36.1 Extraintestinal infections due to Entamoeba** 

**1A36.10** Amoebic liver abscess 

***Inclusions:*** Hepatic amoebiasis 

**1A36.11** Amoebic lung abscess 

**1A36.12** Cutaneous amoebiasis 

**1A36.1Y** Amoebiasis of other specified sites 

**1A36.Z Amoebiasis, unspecified** 

 1A3Y **Other specified protozoal intestinal infections** 

 1A3Z **Protozoal intestinal infections, unspecified** 

 1A40 **Gastroenteritis or colitis without specification of infectious agent *Inclusions:*** enteritis septic 

gastroenteritis septic 

***Exclusions:*** Noninfectious neonatal diarrhoea (KB8C) 

noninfective diarrhoea (ME05.1) 

**1A40.0 Gastroenteritis or colitis without specification of origin** 

There is no mention whether the gastroenteritis or colitis is infectious or non infectious. 

**1A40.Z Infectious gastroenteritis or colitis without specification of infectious agent**

50 ICD-11 MMS    
Predominantly sexually transmitted infections (1A60‑1A9Z) 

***Exclusions:*** Nonspecific and nongonococcal urethritis (GC02.1) 

Arthropathy following genitourinary infection (FA11.2) 

***Coded Elsewhere:*** Sexually transmissible viral hepatitis 

Herpes simplex labialis (1F00.01) 

Herpes simplex gingivostomatitis (1F00.02) 

Vulvovaginal candidosis (1F23.10) 

Candida balanoposthitis (1F23.11) 

Human immunodeficiency virus disease (1C60-1C62.Z) 

Other infections with a predominantly sexual mode of transmission complicating  pregnancy, childbirth or the puerperium (JB63.3) 

Candidosis of external genitalia (1F23.1Z) 

Anogenital molluscum contagiosum (1E76) 

Syphilis (1A60‑1A6Z) 

A predominantly sexually transmitted infection caused by Treponema pallidum ssp. pallidum. 

***Coded Elsewhere:*** Syphilis complicating pregnancy, childbirth or the puerperium (JB63.1)  1A60 **Congenital syphilis**   
A disease caused by an infection with the gram-negative bacteria Treponema  pallidum pallidum in utero. This disease may present with clinical signs depending  on the stage of disease. Transmission is by vertical transmission. 

**1A60.0 Early congenital syphilis, symptomatic** 

A disease affecting newborns or children up to 2 years of age, caused by an  infection with the gram-negative bacteria Treponema pallidum pallidum in utero.  This disease is characterised by premature birth, hepatosplenomegaly, skeletal  abnormalities, and bullous skin disease. Transmission is by vertical transmission. 

**1A60.1 Early congenital syphilis, latent** 

**1A60.2 Late congenital syphilitic oculopathy** 

This is a late congenital, sexually transmitted infection caused by the spirochete  bacterium Treponema pallidum subspecies pallidum. This diagnosis is with  oculopathy. 

**1A60.3 Late congenital neurosyphilis** 

Neurological sequelae of longstanding (\> 2 years) untreated congenital  neurosyphilis include mental delay, hydrocephalus, seizures, cerebral infarction and  cranial nerve palsies. 

**1A60.4 Other late congenital syphilis, symptomatic** 

**1A60.5 Late congenital syphilis, latent** 

**1A60.Z Congenital syphilis, unspecified**

ICD-11 MMS 51   
 1A61 **Early syphilis** 

A disease caused by an infection with the gram-negative bacteria Treponema  pallidum pallidum, including primary and secondary stages of syphilis, and early  latent syphilis of less than 2 years duration. This disease is characterised by a  single chancre in the primary stage, and diffuse rash in the secondary stage.  Transmission is commonly by sexual contact. 

***Exclusions:*** Early congenital syphilis (1A60) 

**1A61.0 Primary genital syphilis** 

A disease caused by an infection with the gram-negative bacteria Treponema  pallidum pallidum. This disease is characterised by a single chancre in the genital  region. Transmission is commonly by sexual contact. 

**1A61.1 Primary anal syphilis** 

**1A61.2 Primary syphilis of other sites** 

**1A61.3 Secondary syphilis of skin or mucous membranes** 

A disease caused by an infection with Treponema pallidum pallidum. This disease  is characterised by lesions of the skin and mucous membranes. Transmission is  commonly by sexual contact. 

**1A61.4 Secondary syphilis of other sites** 

A disease caused by an infection with the gram-negative bacteria Treponema  pallidum pallidum. This disease is characterised by less common symptoms of  syphilis, including hepatitis, kidney disease, arthritis, periostitis, optic neuritis,  uveitis, or interstitial keratitis. Transmission is commonly by sexual contact. 

**1A61.5 Latent early syphilis** 

A disease caused by an infection with the gram-negative bacteria Treponema  pallidum pallidum. This disease is characterised by serologic proof of infection  without symptoms of disease less than 1 year after secondary syphilis.  Transmission is commonly by sexual contact. 

**1A61.Y Other specified early syphilis** 

**1A61.Z Early syphilis, unspecified** 

 1A62 **Late syphilis** 

A disease caused by an infection with the gram-negative bacteria Treponema  pallidum pallidum. This disease is characterised by gummas, neurological  abnormalities, or cardiac abnormalities. Clinical signs normally manifest  approximately 3-15 years after initial infection. Transmission is commonly by sexual  contact. 

***Exclusions:*** Late congenital syphilis (1A60)

52 ICD-11 MMS    
**1A62.0 Neurosyphilis** 

A disease of the brain or spinal cord caused by an infection with the gram-negative  bacteria Treponema pallidum pallidum. This disease is characterised by four  different forms: meningovascular, tabes dorsalis, general paresis, or may be  asymptomatic. Clinical signs normally manifest approximately 4-25 years after initial  infection. Transmission is commonly by sexual contact. 

**1A62.00** Asymptomatic neurosyphilis 

**1A62.01** Symptomatic late neurosyphilis 

A diverse constellation of neuropsychiatric signs resulting from prolonged untreated  or inadequately treated syphilis. The protean clinical manifestations include chronic,  insidious meningeal inflammation with cranial nerve palsy, cognitive and/or  behavioural impairment, ataxia, stroke, seizures and visual or auditory impairment. 

***Coded Elsewhere:*** Dementia due to neurosyphilis (6D85.Y) 

Meningitis due to Treponema pallidum (1D01.0Y) 

**1A62.0Z** Neurosyphilis, unspecified 

**1A62.1 Cardiovascular late syphilis** 

This is a late, sexually transmitted infection caused by the spirochete bacterium  Treponema pallidum subspecies pallidum. This diagnosis is involving the  cardiovascular area. 

**1A62.2 Symptomatic late syphilis of other sites** 

**1A62.20** Ocular late syphilis 

This is a late, sexually transmitted infection caused by the spirochete bacterium  Treponema pallidum subspecies pallidum. This diagnosis is with ocular. 

**1A62.21** Late syphilis involving the musculoskeletal system 

This is a late, sexually transmitted infection caused by the spirochete bacterium  Treponema pallidum subspecies pallidum. This diagnosis is involving the  musculoskeletal system. 

**1A62.22** Late syphilis of skin or mucous membranes 

This is a late, sexually transmitted infection caused by the spirochete bacterium  Treponema pallidum subspecies pallidum. This diagnosis is involving the skin and  mucous membranes. 

**1A62.2Y** Symptomatic late syphilis of other specified sites 

**1A62.2Z** Symptomatic late syphilis of unspecified site 

**1A62.Y Other specified late syphilis** 

**1A62.Z Late syphilis, unspecified**

ICD-11 MMS 53   
 1A63 **Latent syphilis, unspecified as early or late** 

A disease caused by an infection with the gram-negative bacteria Treponema  pallidum pallidum. This disease is characterised by serologic proof of infection  without symptoms of disease. Transmission is commonly by sexual contact. 

***Inclusions:*** Positive serological reaction for syphilis 

 1A6Z **Syphilis, unspecified** 

Gonococcal infection (1A70‑1A7Z) 

A condition caused by an infection with the gram-negative bacteria Neisseria gonorrhoeae.  Transmission is by sexual contact. Confirmation is by identification of Neisseria gonorrhoeae. 

***Exclusions:*** Neonatal conjunctivitis or dacryocystitis due to Neisseria gonorrhoeae (KA65.0) ***Coded Elsewhere:*** Gonorrhoea complicating pregnancy, childbirth or the puerperium (JB63.2)  1A70 **Gonococcal genitourinary infection** 

**1A70.0 Gonococcal infection of lower genitourinary tract without periurethral or  accessory gland abscess** 

***Exclusions:*** Gonococcal infection of lower genitourinary tract with    
periurethral or accessory gland abscess (1A70.1) 

**1A70.00** Gonorrhoea of penis 

**1A70.0Y** Other specified gonococcal infection of lower genitourinary tract without periurethral  or accessory gland abscess 

**1A70.0Z** Gonococcal infection of lower genitourinary tract without periurethral or accessory  gland abscess, unspecified 

**1A70.1 Gonococcal infection of lower genitourinary tract with periurethral or  accessory gland abscess** 

**1A70.Y Gonococcal infection of other specified genitourinary organ 1A70.Z Gonococcal genitourinary infection, unspecified** 

 1A71 **Gonococcal pelviperitonitis** 

This is an inflammation of the peritoneum, the thin tissue that lines the inner wall of  the abdomen and covers most of the abdominal organs. 

 1A72 **Gonococcal infection of other sites** 

**1A72.0 Gonococcal infection of musculoskeletal system** 

This is a species of Gram-negative coffee bean-shaped diplococci bacteria  responsible for the sexually transmitted infection gonorrhoea. This diagnosis is of  the musculoskeletal system. 

**1A72.1 Gonococcal infection of rectum** 

This is a species of Gram-negative coffee bean-shaped diplococci bacteria  responsible for the sexually transmitted infection gonorrhoea of the rectum.

54 ICD-11 MMS    
**1A72.2 Gonococcal infection of anus** 

This is a species of Gram-negative coffee bean-shaped diplococci bacteria  responsible for the sexually transmitted infection gonorrhoea. This diagnosis is of  the anus. 

**1A72.3 Gonococcal pharyngitis** 

**1A72.4 Gonococcal infection of eye** 

This is a species of Gram-negative coffee bean-shaped diplococci bacteria  responsible for the sexually transmitted infection gonorrhoea. This diagnosis is of  the eye. 

***Coded Elsewhere:*** Neonatal conjunctivitis or dacryocystitis due to Neisseria  gonorrhoeae (KA65.0) 

**1A72.Y Gonococcal infection of other specified sites** 

 1A73 **Disseminated gonococcal infection** 

Disseminated gonococcal infection occurs when there is bacteremic dissemination  of Neisseria gonorrhoeae from its initial focus of infection mainly in female pelvic  organs. It manifests as pain and swelling around one or more joints, intermittent  crops of erythematous papules and pustules on the limbs, fever and rigors. Blood  cultures may be but are not always positive. 

 1A7Z **Gonococcal infection, unspecified** 

Sexually transmissible infections due to chlamydia (1A80‑1A8Z) 

An infection with the gram-negative intracellular bacteria Chlamydia trachomatis. This infection may  be asymptomatic or characterised by fever, painful urination, urinary urgency, dyspareunia, vaginal  bleeding or discharge, pain in the abdomen in females and by fever, urethritis, painful urination,  discharge from the penis, swollen or tender testicles in males. Transmission is by anal, vaginal, or oral  sex. Confirmation is by identification of Chlamydia trachomatis. 

***Exclusions:*** Chlamydia trachomatis dacryoadenitis (9A10.0) 

Chlamydial conjunctivitis (1C20) 

Trachoma (1C23) 

 1A80 **Chlamydial lymphogranuloma** 

A disease of the inguinal lymph glands, caused by an infection with the gram negative bacteria Chlamydia trachomatis. This disease is characterised by a genital  ulcer, buboes, abscesses in the groin, blood in faeces, tenesmus, or proctocolitis.  Transmission is by sexual contact. Confirmation is by identification of Chlamydia  trachomatis in a blood sample or by polymerase chain reaction tests. 

***Inclusions:*** Durand-Nicolas-Favre disease

ICD-11 MMS 55   
 1A81 **Non-ulcerative sexually transmitted chlamydial infection *Exclusions:*** Neonatal chlamydial pneumonia (KB24) 

Neonatal conjunctivitis due to Chlamydia (KA65.0) 

Chlamydial lymphogranuloma (1A80) 

Chlamydial peritonitis (1C21) 

Trachoma (1C23) 

**1A81.0 Chlamydial infection of lower genitourinary tract** 

**1A81.1 Chlamydial infection of internal reproductive organs** 

**1A81.Y Non-ulcerative sexually transmitted chlamydial infection of other specified  site** 

**1A81.Z Non-ulcerative sexually transmitted chlamydial infection of unspecified site ** 1A8Y **Other specified sexually transmissible infections due to chlamydia ** 1A8Z **Sexually transmissible infections due to chlamydia, unspecified** 

 1A90 **Chancroid** 

A disease caused by an infection with the gram-negative bacteria Haemophilus  ducreyi. This disease is characterised by painful ulcer(s) on the genitalia.  Transmission is by sexual contact. Confirmation is by identification of Haemophilus  ducreyi from the ulcer exudate. 

***Inclusions:*** Ulcus molle 

 1A91 **Granuloma inguinale** 

A disease caused by infection with the gram-negative bacterium Klebsiella  granulomatis. It commonly presents with painless genital ulceration following  contact with an infected sexual partner. Small, painless nodules appear after an  incubation period of about 10–40 days; later the nodules break down to create  open, fleshy, oozing ulcers which gradually extend, mutilating the infected tissue.  The lesions occur at the region of contact and are typically found on the shaft of the  penis, the labia, or the perineum. 

***Inclusions:*** Donovanosis 

 1A92 **Trichomoniasis** 

A disease caused by an infection with the protozoan parasite Trichomonas. This  disease presents with symptoms depending on the site of infection. 

***Coded Elsewhere:*** Intestinal trichomoniasis (1A3Y) 

 1A93 **Sexually transmissible infestations** 

***Coded Elsewhere:*** Scabies (1G04) 

Pubic infestation by Pthirus pubis (1G03)

56 ICD-11 MMS    
 1A94 **Anogenital herpes simplex infection** 

A condition of the anogenital region, caused by an infection with herpes simplex  virus type 1 or 2\. This condition is characterised by vesicles, or may be  asymptomatic. Transmission is by sexual contact. Confirmation is by identification of  herpes simplex virus type 1 or 2\. 

**1A94.0 Herpes simplex infection of genitalia or urogenital tract** Herpes simplex infection affecting the vulva and vagina in women and the penis in  men. It is more commonly due to infection with Herpes simplex type 2 virus than  with type 1 virus. 

**1A94.1 Herpes simplex infection of perianal skin or rectum** 

Herpes simplex infection of perianal skin and rectum. This is commonly due to  Herpes simplex virus type 2 and acquired through anal sexual contact. 

**1A94.Z Anogenital herpes simplex infection without further specification** 

 1A95 **Anogenital warts** 

Anogenital warts are due to an infection of anogenital skin and mucous membranes  by certain human papilloma viruses, most commonly HPV subtypes 6, 11, 16 and  18\. Transmission is predominantly by sexual contact. They manifest typically as flat  plaques or papillomatous, keratinous growths on and adjacent to the external  genitalia and anus. Some HPV subtypes, including types 16 and 18, are oncogenic  and predispose to the development of anogenital cancers. 

***Coded Elsewhere:*** Anogenital verrucous carcinoma of Buschke and Lowenstein  (2C31.0) 

**1A95.0 Anal warts** 

Infection of the anus or perianal skin by human papillomavirus (HPV). Although the  majority of such infections are sexually transmitted and caused by HPV subtypes  responsible for genital warts, autoinoculation from common warts, especially on the  hands in children, may also cause perianal warts. 

***Inclusions:*** Condylomata acuminata of anus 

**1A95.1 Genital warts** 

Infection of anogenital mucosa or skin by the human papillomavirus. The infection is  commonly asymptomatic but manifests typically as flat, papular or pedunculated  growths depending on the site of infection. Transmission is normally by sexual  contact. 

**1A95.2 Extragenital condylomata acuminata** 

Anogenital warts transmitted to extragenital sites (i.e. beyond the anogenital  region). This may be through autoinoculation of anogenital wart virus to moist,  intertriginous sites on the abdomen or under the breasts, or as a result of sexual  activity, particularly to the lips and oral cavity. 

***Inclusions:*** Anogenital warts affecting sites other than the anogenital area **1A95.Z Anogenital warts, unspecified** 

 1A9Y **Other specified predominantly sexually transmitted infections**

ICD-11 MMS 57   
 1A9Z **Predominantly sexually transmitted infections, unspecified** Mycobacterial diseases (1B10‑1B2Z) 

Tuberculosis (1B10‑1B1Z) 

A disease caused by an infection with bacteria of the Mycobacterium tuberculosis complex. This  disease presents with symptoms depending on the site of infection. Transmission is commonly by  inhalation of infected respiratory secretions. 

***Inclusions:*** Infections due to Mycobacterium tuberculosis and Mycobacterium bovis ***Exclusions:*** Pneumoconiosis associated with tuberculosis (CA60.3) 

***Coded Elsewhere:*** Congenital tuberculosis (KA61.0) 

Tuberculosis complicating pregnancy, childbirth or the puerperium (JB63.0) 

HIV disease clinical stage 1 associated with tuberculosis (1C60.0) 

HIV disease clinical stage 2 associated with tuberculosis (1C60.1) 

HIV disease clinical stage 3 associated with tuberculosis (1C60.2) 

HIV disease clinical stage 4 associated with tuberculosis (1C60.3) 

Human immunodeficiency virus disease associated with tuberculosis (1C60) 

Tuberculosis of orbit (9A22.2) 

 1B10 **Tuberculosis of the respiratory system** 

This is a progressive or chronic disease resulting from infection with the bacterium  Mycobacterium tuberculosis or other bacteria in the M. tuberculosis complex: M.  bovis, M. africanum, M. canetti, M. microti and M. pinnipedii. The infection is limited  to the respiratory system. 

**1B10.0 Respiratory tuberculosis, confirmed** 

A disease of the respiratory tract, caused by an infection with the bacteria  Mycobacterium tuberculosis, which has been confirmed by laboratory testing. This  disease is characterised by chronic cough, and sputum production that may be  haemorrhagic. Transmission is commonly by inhalation of infected respiratory  secretions. Confirmation is by identification of Mycobacterium tuberculosis in clinical  samples. 

**1B10.1 Respiratory tuberculosis, not confirmed** 

A disease of the respiratory tract, caused by an infection with the bacteria  Mycobacterium tuberculosis, which has not been confirmed. This disease is  characterised by a chronic cough, and sputum production that may be  haemorrhagic. Transmission is commonly by inhalation of infected respiratory  secretions. 

**1B10.Z Respiratory tuberculosis, without mention of bacteriological or histological  confirmation**

58 ICD-11 MMS    
 1B11 **Tuberculosis of the nervous system** 

A disease of the central nervous system, caused by an infection with bacteria of the  Mycobacterium tuberculosis complex. This disease is characterised by neurological  deficits depending on the site affected. Transmission is through haematogenous  spread to the nervous system after inhalation of infected respiratory secretions.  Confirmation is by identification of bacteria of the Mycobacterium tuberculosis  complex in the cerebrospinal fluid. 

**1B11.0 Tuberculous meningitis** 

A disease of the meninges, caused by an infection with the bacteria Mycobacterium  tuberculosis. This disease is characterised by fever, headache, or neurological  deficits. Transmission is through haematogenous spread to the meninges after  inhalation of infected respiratory secretions. Confirmation is by identification of  Mycobacterium tuberculosis in the cerebrospinal fluid. 

***Inclusions:*** Tuberculous leptomeningitis 

**1B11.1 Tuberculous meningoencephalitis** 

**1B11.2 Meningeal tuberculoma** 

Meningeal tuberculomas are conglomerate caseous foci within the meninges of the  brain, caused by dissemination of tuberculosis to the central nervous system. 

***Inclusions:*** Tuberculoma of meninges 

**1B11.3 Tuberculous granuloma of brain** 

**1B11.Y Other tuberculosis of nervous system** 

**1B11.Z Tuberculosis of the nervous system, unspecified** 

 1B12 **Tuberculosis of other systems and organs** 

**1B12.0 Tuberculosis of heart** 

Mycobacterium tuberculosis infection involving the heart and pericardium 

**1B12.1 Tuberculosis of eye** 

Tuberculosis involving the eye. This may manifest in multiple different ways  including keratoconjunctivitis, episcleritis, anterior uveitis and posterior uveitis 

***Exclusions:*** lupus vulgaris of eyelid (1B12.8) 

**1B12.2 Tuberculosis of ear** 

This is a common, and in many cases lethal, infectious disease caused by various  strains of mycobacteria, usually Mycobacterium tuberculosis. This diagnosis is of  the ear. 

***Exclusions:*** tuberculosis of skin of external ear (1B12.8) 

Tuberculous mastoiditis (1B12.40) 

**1B12.3 Tuberculosis of endocrine glands** 

Infection of endocrine glands by Mycobacterium tuberculosis with resultant  endocrine disturbances including adrenal or pituitary failure. 

***Coded Elsewhere:*** Tuberculous Addison disease (1B12.3)

ICD-11 MMS 59   
**1B12.4 Tuberculosis of the musculoskeletal system** 

***Coded Elsewhere:*** Mycobacterial infection of vertebra (FA90.1) 

**1B12.40** Tuberculosis of bones or joints 

A disease of the bones and joints, caused by an infection with the bacteria  Mycobacterium tuberculosis. This disease commonly presents with bone pain, joint  inflammation, loss of movement or feeling in the affected bone or joint, and weak  bones prone to fracture. Transmission is through haematogenous spread to the  bones and joints after inhalation of infected respiratory secretions. Confirmation is  by identification of Mycobacterium tuberculosis in biopsy samples of the affected  site. 

**1B12.41** Tuberculous myositis 

**1B12.4Y** Tuberculosis of other specified part of the musculoskeletal system **1B12.4Z** Tuberculosis of the musculoskeletal system, unspecified 

**1B12.5 Tuberculosis of the genitourinary system** 

Tuberculosis involving the urinary tract and/or reproductive organs. The primary site  of infection is most commonly the kidney as a result of haematogenous spread from  distant sites: infection may then spread further down the urinary tract and/or to the  reproductive organs. Genital infection may be sexually transmitted. 

**1B12.6 Tuberculous peripheral lymphadenopathy** 

A disease of the peripheral lymph nodes, caused by an infection with the bacteria  Mycobacterium tuberculosis. This disease is characterised by inflammation of the  peripheral lymph nodes, typically the cervical lymph nodes. Transmission is through  haematogenous spread to the peripheral lymph nodes after inhalation of infected  respiratory secretions. Confirmation is by identification of Mycobacterium  tuberculosis from lymph node biopsies. 

***Inclusions:*** Tuberculous adenitis 

***Exclusions:*** Tuberculosis of intrathoracic lymph nodes, confirmed    
bacteriologically or histologically (1B10.0) 

Tuberculosis of intrathoracic lymph nodes, without mention of    
bacteriological or histological confirmation (1B10) 

**1B12.7 Tuberculosis of the digestive system** 

Tuberculosis of the digestive tract or hepatobiliary system 

**1B12.8 Cutaneous tuberculosis** 

Tuberculosis involving the skin and mucous membranes including lupus vulgaris,  scrofuloderma and periorificial tuberculosis. 

***Exclusions:*** Tuberculids (EA40‑EA5Z) 

Skin complications of BCG immunisation (EA51) 

***Coded Elsewhere:*** Acute miliary cutaneous tuberculosis (1B13.0) 

**1B12.Y Tuberculosis of other specified organ or site** 

 1B13 **Miliary tuberculosis**

60 ICD-11 MMS    
**1B13.0 Acute miliary tuberculosis of a single specified site** 

A disease caused by an infection with the bacteria Mycobacterium tuberculosis that  is disseminated through the body, and affecting a specific body site. This disease is  characterised by numerous small lesions of 1-5 millimetre(s) in any organ, and  fever. Transmission is commonly by inhalation of infected respiratory secretions.  Confirmation is by radiography, CT, ultrasonography, and identification of  Mycobacterium tuberculosis, depending on the site affected. 

**1B13.1 Acute miliary tuberculosis of multiple sites** 

A disease caused by an infection with the bacteria Mycobacterium tuberculosis that  is disseminated through the body, and affecting multiple body sites. This disease is  characterised by numerous small lesions of 1-5 millimetre(s) in more than one  organ, and fever. Transmission is commonly by inhalation of infected respiratory  secretions. Confirmation is by radiography, advanced imaging, ultrasonography,  and identification of Mycobacterium tuberculosis, depending on the sites affected. 

**1B13.2 Acute miliary tuberculosis, unspecified site** 

**1B13.Y Other specified miliary tuberculosis** 

**1B13.Z Miliary tuberculosis, unspecified** 

 1B14 **Latent tuberculosis** 

 1B1Y **Other specified tuberculosis** 

 1B1Z **Tuberculosis, unspecified** 

 1B20 **Leprosy** 

A disease caused by an infection with Mycobacterium leprae. This disease  commonly presents with a long asymptomatic period followed by granulomatous  lesions of the skin, respiratory tract, and peripheral nerves. Transmission is  commonly by droplet transmission. Confirmation is by identification of  Mycobacterium leprae with skin biopsy. 

***Inclusions:*** Infection due to Mycobacterium leprae 

**1B20.0 Paucibacillary leprosy** 

**1B20.1 Multibacillary leprosy** 

**1B20.2 Leprosy reactions** 

**1B20.20** Type I leprosy reaction 

This phenomenon, also named “upgrading reaction,” occurs in borderline leprosy  states and is associated with an increase in cell-mediated immunity. It occurs  typically within the first 6 months of treatment in previously untreated patients but  may be related to stress, intercurrent infections, or pregnancy. Clinical features  include inflammatory swelling, erythema and occasionally ulceration of existing  lesions, constitutional symptoms and neuritis. If the neuritis is not treated promptly  permanent motor nerve damage may ensue.

ICD-11 MMS 61   
**1B20.21** Type II leprosy reaction 

This phenomenon, also named downgrading reaction, occurs in borderline leprosy  states and is associated with a decrease in cell-mediated immunity with a shift  towards the lepromatous end of the clinical spectrum. 

**1B20.3 Complications of leprosy** 

**1B20.Z Leprosy, unspecified** 

 1B21 **Infections due to non-tuberculous mycobacteria** 

Any condition caused by an infection with Mycobacteria excluding infections due to  Mycobacterium tuberculosis complex and Mycobacterium leprae. These conditions  commonly present with lung disease; however, symptoms are dependent on the site  of infection. Transmission is by direct contact with non-tuberculous Mycobacteria in  the environment. Confirmation is by identification of non-tuberculous Mycobacteria  from the affected site(s). 

***Exclusions:*** Leprosy (1B20) 

Tuberculosis (1B10‑1B1Z) 

**1B21.0 Pulmonary infection due to non-tuberculous mycobacterium** A condition of the pulmonary system, caused by an infection with the bacteria  Mycobacterium (excluding infections due to Mycobacterium tuberculosis and  Mycobacterium leprae). This disease is characterised by cough, fever, weight loss,  and fatigue. Transmission is by direct contact with Mycobacterium in the  environment. 

**1B21.1 Non-tuberculous mycobacterial lymphadenitis** 

**1B21.2 Cutaneous non-tuberculous mycobacterial infection** 

***Exclusions:*** Leprosy (1B20) 

Tuberculosis (1B10‑1B1Z) 

**1B21.20** Mycobacterium ulcerans infection 

Mycobacterium ulcerans infection (Buruli ulcer) typically presents as a  subcutaneous nodule which breaks down to form a deep painless ulcer which  commonly reaches a size of 15 cm in diameter but may extend further to cause  extensive tissue damage. The organism is found in wetlands of tropical and  subtropical regions of the world, particularly Africa \[Dermatology TAG\]. 

**1B21.2Y** Cutaneous infection due to other specified non-tuberculous mycobacteria **1B21.2Z** Cutaneous infection due to unspecified non-tuberculous mycobacteria **1B21.3 Disseminated non-tuberculous mycobacterial infection** 

**1B21.4 Gastrointestinal non-tuberculous mycobacterial infection 1B21.Y Non-tuberculous mycobacterial infection of other specified site 1B21.Z Non-tuberculous mycobacterial infection of unspecified site ** 1B2Y **Other specified mycobacterial diseases**

62 ICD-11 MMS    
 1B2Z **Mycobacterial diseases, unspecified** 

Certain staphylococcal or streptococcal diseases (1B40‑1B5Z) 

***Coded Elsewhere:*** Toxic shock syndrome (1C45) 

Streptococcal tonsillitis (CA03.0) 

Rheumatic myocarditis (BC42.3) 

Chronic rheumatic pericarditis (BB21) 

Acute staphylococcal tonsillitis (CA03.Y) 

Acute rheumatic fever (1B40‑1B42) 

A disease of the connective tissue, caused by an infection with the gram-positive bacteria  Streptococcus pyogenes (the disease may also affect the heart, joints, central nervous system,  subcutaneous tissues, or skin). This disease is characterised by fever, polyarthritis, carditis,  subcutaneous nodules, or erythema marginatum. Transmission is through haematogenous spread to  other parts of the body after direct or indirect contact. Confirmation is by electrocardiography,  sedimentation rate, or identification of Streptococcus pyogenes in a blood sample. 

***Coded Elsewhere:*** Erythema marginatum rheumaticum (EA50.0) 

 1B40 **Acute rheumatic fever without mention of heart involvement 1B40.0 Rheumatic arthritis, acute or subacute** 

**1B40.Y Other specified acute rheumatic fever without mention of heart involvement 1B40.Z Acute rheumatic fever without mention of heart involvement, unspecified**

ICD-11 MMS 63   
 1B41 **Acute rheumatic fever with heart involvement** 

A disease of the cardiovascular system, caused as a result of rheumatic fever.  Rheumatic heart disease is characterised by repeated inflammation with fibrinous  repair. This disease may present with cardinal anatomic changes of the valve  including leaflet thickening, commissural fusion, and shortening and thickening of  the tendinous cords. Inflammation and valve scarring may also occur. Confirmation  is by a thoracic radiography or echocardiography. 

***Exclusions:*** Rheumatic mitral valve stenosis (BB60.0) 

Rheumatic mitral valve insufficiency (BB61.0) 

Rheumatic mitral valve prolapse (BB62.0) 

Rheumatic mitral stenosis with insufficiency (BB63.0) 

Rheumatic aortic valve stenosis (BB70.0) 

Rheumatic aortic valve insufficiency (BB71.0) 

Rheumatic aortic stenosis with insufficiency (BB72.0) 

Rheumatic tricuspid valve stenosis (BB80.0) 

Rheumatic tricuspid valve insufficiency (BB81.0) 

Rheumatic tricuspid valve stenosis with insufficiency (BB82.0) 

Rheumatic pulmonary valve stenosis (BB90.0) 

Rheumatic pulmonary valve insufficiency (BB91.0) 

Rheumatic pulmonary valve stenosis with insufficiency    
(BB92.0) 

**1B41.0 Acute rheumatic pericarditis** 

A disease of the pericardium, caused by acute rheumatic fever. This disease is  characterised by fever, dry cough, rapid heart rate, fatigue, or low blood pressure.  Confirmation is by echocardiography, or thoracic radiography. 

**1B41.1 Acute rheumatic endocarditis** 

A disease of the endocardium, caused as a result of acute rheumatic fever. This  disease is characterised by a high fever, chills, shortness of breath, rapid or  irregular heartbeat, coughing up of blood, abdominal pain or septicaemia. This  disease commonly presents with valvular involvement. Confirmation is by  echocardiography. 

**1B41.10** Rheumatic aortitis 

**1B41.1Y** Other specified acute rheumatic endocarditis 

**1B41.1Z** Acute rheumatic endocarditis, unspecified 

**1B41.2 Acute rheumatic myocarditis** 

Acute rheumatic myocarditis is cardiac inflammation associated with acute  rheumatic fever triggered by an autoimmune reaction to group A streptococci  infection resulting in pancarditis involving inflammation of the myocardium,  endocardium, and epicardium, usually with left-sided valvar involvement. 

**1B41.Y Other acute rheumatic heart disease**

64 ICD-11 MMS    
**1B41.Z Acute rheumatic heart disease, unspecified** 

 1B42 **Rheumatic chorea** 

***Exclusions:*** Huntington chorea (8A01.10) 

 1B50 **Scarlet fever** 

A disease caused by an infection with the gram-positive bacteria Streptococcus  pyogenes. This disease is characterised by a sore throat, fever, and a red rash.  Transmission is commonly by inhalation of infected respiratory secretions, direct  skin contact, or indirect contact. 

***Inclusions:*** Scarlatina NOS 

***Exclusions:*** streptococcal sore throat (1B51) 

Staphylococcal scarlatina (EA50.3) 

 1B51 **Streptococcal pharyngitis** 

A disease of the pharynx, caused by an infection with the gram-positive bacteria  Streptococcus pyogenes. This disease is characterised by fever, sore throat,  tonsillar exudates, or large cervical lymph nodes. Transmission is commonly by  inhalation of infected respiratory secretions, or indirect contact. Confirmation is by  identification of Streptococcus pyogenes from a throat swab. 

***Inclusions:*** Streptococcal sore throat 

***Exclusions:*** Scarlet fever (1B50) 

 1B53 **Meningitis due to Streptococcus** 

A disease of the meninges, caused by an infection with the gram-positive bacteria  genus Streptococcus. This disease commonly presents with nausea, vomiting,  photophobia, and confusion. Transmission is through haematogenous spread to the  meninges after inhalation of infected respiratory secretions. Confirmation is by  identification of Streptococcus in the cerebrospinal fluid. 

***Inclusions:*** Streptococcal meningitis 

 1B54 **Meningitis due to Staphylococcus** 

A disease of the meninges, caused by an infection with the gram-positive bacteria  genus Staphylococcus. This disease commonly presents with acute inflammation of  the meninges causing headache, fever, stiff neck, or neurological deficits.  Confirmation is by identification of Staphylococcus in the cerebrospinal fluid. 

***Inclusions:*** Staphylococcal meningitis 

 1B5Y **Other specified staphylococcal or streptococcal diseases ** 1B5Z **Staphylococcal or streptococcal diseases, unspecified**

ICD-11 MMS 65   
Pyogenic bacterial infections of the skin or subcutaneous tissues (1B70‑1B7Z) ***Coded Elsewhere:*** Acute bacterial paronychia (EE12.0) 

 1B70 **Bacterial cellulitis, erysipelas or lymphangitis** 

Diffuse, spreading infections of skin and soft tissues by a range of bacterial  organisms, most commonly beta-haemolytic streptococci and Staphylococcus  aureus. The clinical presentation is dependent not only on the organism but also on  the manner in which it invades the tissues. 

***Exclusions:*** Eosinophilic cellulitis (EB30) 

**1B70.0 Erysipelas** 

***Exclusions:*** postpartum or puerperal erysipelas (JB40) 

**1B70.00** Erysipelas of face 

**1B70.01** Erysipelas of external ear 

A rapidly expanding diffuse superficial dermal streptococcal infection involving the  external ear. In contrast with infective otitis externa, the skin of the auricle is often  initially healthy except at a point of entry for beta-haemolytic streptococci  (commonly at a fissure behind the ear or where the ear lobule is attached to the  side of the head) and systemic features including fever and malaise are common. 

**1B70.02** Erysipelas of lower limb 

**1B70.0Y** Erysipelas of other specified site 

**1B70.0Z** Erysipelas, unspecified 

**1B70.1 Streptococcal cellulitis of skin** 

***Exclusions:*** Orbital cellulitis (9A21.0) 

Cellulitis of external ear (AA01) 

anal cellulitis (DB70.00) 

vulvar cellulitis (GA00.0) 

Cellulitis of penis (GB06) 

Inflammatory disorders of scrotum (GB07.2) 

perirectal cellulitis (DB36.10) 

Superficial incisional site infection (NE81.20) 

**1B70.2 Staphylococcal cellulitis of skin** 

***Exclusions:*** Orbital cellulitis (9A21.0) 

Cellulitis of external ear (AA01) 

anal cellulitis (DB70.00) 

vulvar cellulitis (GA00.0) 

Cellulitis of penis (GB06) 

Inflammatory disorders of scrotum (GB07.2) 

perirectal cellulitis (DB36.10) 

Superficial incisional site infection (NE81.20)

66 ICD-11 MMS    
**1B70.3 Ascending bacterial lymphangitis** 

A complication of a focal acute pyogenic bacterial infection in which the draining  lymphatics become red, inflamed and tender as the result of ascending infection. It  is most commonly caused by Streptococcus pyogenes. 

**1B70.Y Bacterial cellulitis or lymphangitis due to other specified bacterium 1B70.Z Bacterial cellulitis or lymphangitis due to unspecified bacterium ** 1B71 **Necrotising fasciitis** 

**1B71.0 Streptococcal necrotising fasciitis** 

***Exclusions:*** Neonatal necrotising fasciitis (1B71.2) 

***Coded Elsewhere:*** Neonatal streptococcal necrotising fasciitis (1B71.2) 

**1B71.1 Polymicrobial necrotising fasciitis** 

***Exclusions:*** Neonatal necrotising fasciitis (1B71.2) 

**1B71.2 Neonatal necrotising fasciitis** 

Neonatal necrotising fasciitis is a life-threatening acute necrotising infection of  fascia, subcutaneous tissues, and overlying skin similar to the condition seen in  adults. It is rare in neonates but, in contrast to the adult form, tends to affect  otherwise healthy babies. It has followed omphalitis, mastitis and postoperative  wound infection, though preceding sites of infection are not always found. It has  more commonly been associated with Staphylococcus aureus than with  streptococcal infection. Gram-negative organisms have also been implicated. It may  cause extensive tissue destruction and mortality is high. 

**1B71.Y Necrotising fasciitis due to other specified bacterial infection 1B71.Z Necrotising fasciitis, unspecified** 

 1B72 **Impetigo** 

A condition of the skin, commonly caused by a secondary infection with the gram positive bacteria Staphylococcus aureus or group A beta haemolytic streptococci.  This condition is characterised by bullous or non-bullous symptoms. Transmission is  by direct contact with an infected individual. Confirmation is by identification of the  infectious agent in a skin sample. 

***Exclusions:*** impetigo herpetiformis (EA90.40) 

Staphylococcal scalded skin syndrome (EA50.2) 

***Coded Elsewhere:*** Otitis externa in impetigo (AA3Y)

ICD-11 MMS 67   
**1B72.0 Bullous impetigo** 

Bullous impetigo is a contagious superficial infection of the skin caused by certain  strains of Staphylococcus aureus which release toxins into the local environment  which are capable of cleaving desmoglein I, a protein involved in intercellular  adhesion of epidermal keratinocytes. In contrast to the very superficial, rapidly shed  and rarely observed blisters of non-bullous impetigo, the bullae of bullous impetigo  are tense and well demarcated, sometimes reaching several centimetres in  diameter before rupture. 

***Coded Elsewhere:*** Neonatal bullous impetigo (EH11) 

**1B72.1 Non-bullous impetigo** 

Non-bullous impetigo is due to superficial skin infection with either Streptococcus  pyogenes or Staphylococcus aureus or both. The very superficial blisters which  form in the upper epidermis are soon shed and rarely seen (cf. bullous impetigo) so  that it normally presents with areas of superficial oozing and crusting on the skin  surface. It often following minor skin injury or on skin damaged by a preexisting  dermatosis such as atopic eczema or scabies. 

**1B72.2 Secondary impetiginisation of the skin** 

Secondary infection of dermatoses such as atopic eczema by streptococci or  staphylococci. 

***Coding Note:*** Code also the causing condition 

**1B72.Y Other specified impetigo** 

**1B72.Z Impetigo, unspecified** 

 1B73 **Ecthyma** 

Ecthyma is a superficial ulcerative bacterial pyoderma. It is characterised by small,  purulent, shallow, punched-out ulcers with thick, brown-black crusts and  surrounding erythema. The commonest form is caused by beta-haemolytic  streptococci, often in association with Staphylococcus aureus. It is associated with  poor hygiene and malnutrition. Ecthyma gangrenosum is an uncommon severe  variant caused by Pseudomonas aeruginosa. 

**1B73.0 Streptococcal ecthyma** 

**1B73.1 Staphylococcal ecthyma** 

Ecthyma due to a monoinfection with Staphylococcus aureus. It is less common  than streptococcal ecthyma. 

**1B73.2 Ecthyma gangrenosum** 

Ecthyma gangrenosum is a potentially life-threatening infection of skin in patients  who are immunocompromised through disease or immunosuppressive therapy. It is  most commonly caused by Pseudomonas aeruginosa though a variety of other  organisms may be implicated. It is characterised by usually painless erythematous  macules or plaques which progress to haemorrhagic blistering and necrosis of the  skin. Lesions may be multiple and widely disseminated, though the anogenital area  is a common site. Pseudomonas can frequently be cultured from the blood. 

***Coded Elsewhere:*** Neonatal ecthyma gangrenosum (EH11)

68 ICD-11 MMS    
**1B73.Y Other specified ecthyma** 

**1B73.Z Ecthyma, unspecified** 

 1B74 **Superficial bacterial folliculitis** 

Bacterial infection of the follicular ostium manifested as follicular papules and  pustules with perifollicular erythema. The most commonly isolated organisms are  coagulase-negative staphylococci and Staphylococcus aureus. The infection may  be acute but is more commonly subacute or chronic; individual lesions heal without  scarring. Commonly affected sites include the scalp, beard area, thighs and  buttocks. 

**1B74.0 Staphylococcus aureus superficial folliculitis** 

Infection of the follicular ostium with Staphylococcus aureus. There is a predilection  for hairy areas including the scalp, beard and thighs. 

**1B74.Y Superficial bacterial folliculitis due to other specified organism 1B74.Z Superficial bacterial folliculitis due to unspecified organism** 

 1B75 **Deep bacterial folliculitis or pyogenic abscess of the skin** Single or multiple focal infections of skin and soft tissues most commonly centred  on the hair follicle and most commonly due to Staphylococcus aureus. Pyogenic  abscesses may develop in other locations in skin which has been injured as a result  of either trauma or surgery. 

**1B75.0 Furuncle** 

A localised infection of a hair follicle by Staphylococcus aureus. It manifests as a  painful swollen purulent mass centred on a hair follicle. 

**1B75.1 Carbuncle** 

A deep follicular pyogenic staphylococcal skin infection involving a group of  adjacent hair follicles. It manifests as a painful boggy mass containing multiple  purulent discharging sinuses. 

**1B75.2 Furunculosis** 

The presence of multiple furuncles, this condition is associated with disorders such  as malnutrition and diabetes mellitus. Treatment-resistant furunculosis may be  associated with Panton-Valentine leucocidin-producing Staphylococcus aureus. 

**1B75.3 Pyogenic abscess of the skin** 

A pus-producing abscess of the skin most commonly due to bacterial infection by  Staphylococcus aureus. It is prone to develop where the normal anatomy is  disturbed as in pilonidal disease, an epidermoid cyst or around foreign bodies such  as surgical sutures. 

***Coded Elsewhere:*** Sacrococcygeal pilonidal abscess (EG63.2) 

Infected epidermoid cyst (EK70.00)

ICD-11 MMS 69   
**1B75.4 Chronic deep bacterial folliculitis** 

A chronic pyogenic infection by Staphylococcus aureus involving the whole depth of  the hair follicle. Sycosis occurs mostly in males after puberty, and commonly  involves the follicles of the beard. Most cases begin in the third or fourth decade.  Unknown host factors appear to be important in the chronicity of the infection.  Extensive follicular destruction and scarring may ensue (lupoid sycosis). 

***Coded Elsewhere:*** Folliculitis cruris pustulosa atrophicans (ED81.0) 

**1B75.Z Deep bacterial folliculitis or pyogenic abscess of the skin, unspecified** 

 1B7Y **Other specified pyogenic bacterial infection of skin or subcutaneous  tissue** 

 1B7Z **Pyogenic bacterial infection of skin or subcutaneous tissue,  unspecified** 

Certain zoonotic bacterial diseases (1B90‑1B9Z) 

This is a group of bacterial diseases that are transmitted to humans by contact with infected  vertebrate animals. 

 1B90 **Rat-bite fevers** 

Any disease caused by an infection with the gram-negative bacteria Streptobacillus  moniliformis or gram-negative bacteria Spirillum minus. This disease presents with  symptoms depending on the bacterial agent. Transmission is through the bite of an  infected rat or rodent. 

**1B90.0 Spirillosis** 

A disease caused by an infection with the gram-negative bacteria Spirillum minus.  This disease is initially characterised by local inflammation, followed by fever,  lymphadenitis, and headache. Transmission is commonly by direct contact through  the bite or scratch of an infected rat. Confirmation is by identification of Spirillum in  blood or tissue samples. 

***Inclusions:*** Sodoku 

**1B90.1 Streptobacillosis** 

A disease caused by an infection with the gram-negative bacteria Streptobacillus  moniliformis. This disease is characterised by systemic illness with fever, chills,  rash, and polyarthralgias. Transmission is commonly by direct contact through the  bite or scratch of an infected rat. Confirmation is by identification of Streptobacillus  in blood or joint samples. 

***Inclusions:*** Epidemic arthritic erythema 

Haverhill fever 

Streptobacillary rat-bite fever

70 ICD-11 MMS    
 1B91 **Leptospirosis** 

A disease caused by an infection with the gram-negative bacteria Leptospira. In the  first phase, this disease is characterised by generalised illness (fever, chills, or  myalgias) or individuals may be asymptomatic; in the second phase, the heart, liver,  kidneys, or brain may be affected by the infection (symptoms are dependent on the  site affected). Transmission is by ingestion of contaminated food or water, droplet  transmission, or direct cutaneous contact. Confirmation is by identification of  Leptospira in samples from the affected individual. 

 1B92 **Glanders** 

A disease caused by an infection with the gram-negative bacteria Burkholderia  mallei. This disease presents with symptoms depending on the route of infection.  Transmission is by contact with tissues or body fluids from infected animals  (typically horses), or inhalation of infected aerosol. Confirmation is by identification  of Burkholderia mallei in blood, sputum, urine, or skin samples. 

***Inclusions:*** Infection due to Pseudomonas mallei 

 1B93 **Plague** 

A disease caused by an infection with the gram-negative bacteria Yersinia pestis.  This disease presents with symptoms depending on the site of infection, and may  be fatal. Transmission is through the bite of an infected flea, by direct contact, or by  droplet transmission. 

**1B93.0 Bubonic plague** 

A disease caused by an infection with the gram-negative bacteria Yersinia pestis.  This disease commonly presents with an infection of the lymph nodes leading to  swelling and pain. This disease may also present with gangrene of the extremities,  chills, malaise, high fever, muscle cramps, or seizures. Transmission is through the  bite of an infected flea, by direct contact, or by droplet transmission. 

**1B93.1 Cellulocutaneous plague** 

Cellulocutaneous plague is a zoonotic disease caused by Yersinia pestis (formerly  known as Pasteurella pestis) involving the skin around the flea bite which  transmitted the pathogen. 

**1B93.2 Pneumonic plague** 

Pneumonic plague is a zoonotic disease caused by Yersinia pestis (formerly known  as Pasteurella pestis) involving the lung. The lungs are seeded by hematogenous  spread or from inhalation of the pathogen. 

**1B93.3 Plague meningitis** 

Plague meningitis is a zoonotic disease caused by Yersinia pestis (formerly known  as Pasteurella pestis) that involves the central nervous system. 

**1B93.Y Other specified plague** 

**1B93.Z Plague, unspecified**

ICD-11 MMS 71   
 1B94 **Tularaemia** 

A disease caused by an infection with Francisella tularensis. This disease is  characterised by fever, chills, headache, and weakness, as well as other symptoms  depending on the route of infection. Transmission is through the bite of an infected  tick or deer fly, by ingestion of contaminated water or food, airborne transmission, or  by direct contact with infected animals. Confirmation is by identification of  Francisella tularensis, or the presence of antibodies to Francisella tularensis, in a  blood or sputum sample. 

***Inclusions:*** deer-fly fever 

rabbit fever 

infection due to Francisella tularensis 

**1B94.0 Ulceroglandular tularaemia** 

**1B94.Y Other specified tularaemia** 

**1B94.Z Tularaemia, unspecified** 

 1B95 **Brucellosis** 

A disease caused by an infection with the gram-negative bacteria Brucella. This  disease is characterised by fever, muscular pain, or sweating. Transmission is by  ingestion of unpasteurized milk and soft cheeses made from infected animals.  Confirmation is by identification of Brucella or antibodies to Brucella. 

***Inclusions:*** Malta fever 

Mediterranean fever 

undulant fever 

***Coded Elsewhere:*** Spondylitis in brucellosis (FA13) 

 1B96 **Erysipeloid** 

A disease caused by an infection with the gram-positive bacteria Erysipelothrix  rhusiopathiae. This disease is characterised by localised cellulitis. Transmission is  by direct cutaneous contact with Erysipelothrix rhusiopathiae, often in individuals  handling seafood and raw meat. 

 1B97 **Anthrax** 

A disease caused by an infection with the gram-positive bacteria Bacillus anthracis.  This disease presents with clinical signs depending on the route of infection.  Transmission is by inhalation, ingestion, or cutaneous contact with Bacillus  anthracis spores. Confirmation is by identification of Bacillus anthracis in a sample,  or detection of antibodies or toxins. 

 1B98 **Cat-scratch disease** 

A disease commonly caused by an infection with the gram-negative bacteria  Bartonella henselae. This disease is characterised by regional lymphadenopathy, or  fever. Transmission is commonly from the scratch or bite of a cat infested with fleas  infected with Bartonella henselae. 

***Inclusions:*** Cat-scratch fever 

Rochalimaea henselae infection

72 ICD-11 MMS    
 1B99 **Pasteurellosis** 

A disease caused by an infection with the gram-negative bacteria Pasteurella. This  disease is characterised by local cellulitis and may lead to other clinical signs  depending on the route of infection. Transmission is commonly by direct contact  through the bite, scratch, or lick from an infected animal, inhalation of infected  respiratory secretions, or ingestion of contaminated meat. Confirmation is by  identification of Pasteurella from the affected individual. 

 1B9A **Extraintestinal yersiniosis** 

A disease caused by an infection with the gram-negative bacteria Yersinia  enterocolitica, excluding infections in the intestinal tract. This disease presents with  symptoms depending on the site of infection, and may lead to a systemic infection.  Transmission is by the faecal-oral route from the ingestion of contaminated food or  water, or direct contact with infected animals or humans. Confirmation is by  identification of Yersinia enterocolitica from affected tissues. 

***Exclusions:*** Enteritis due to Yersinia enterocolitica (1A05) 

Plague (1B93) 

 1B9Z **Unspecified zoonotic bacterial disease** 

Other bacterial diseases (1C10‑1C4Z) 

***Coded Elsewhere:*** Other bacterial infections of the fetus or newborn (KA61) Bacterial duodenitis (DA51.6Y) 

 1C10 **Actinomycosis** 

A disease commonly caused by an infection with the gram-positive bacteria  Actinomyces. This disease is characterised by painful abscesses in the mouth,  lungs, and gastrointestinal tract. Actinomycosis is an endogenous infection whose  causative bacteria originate from the patient's oral and pharyngeal flora. It can  spread by continuity and hematogenously. Confirmation is by identification of  Actinomyces in infected tissue or fluid samples. 

***Exclusions:*** Actinomycetoma (1C43) 

**1C10.0 Pulmonary actinomycosis** 

This is a pulmonary infectious bacterial disease caused by Actinomyces species  such as Actinomyces israelii or A. gerencseriae. It can also be caused by  Propionibacterium propionicus, and the condition is likely to be polymicrobial  aerobic-anaerobic infection. 

**1C10.1 Abdominal actinomycosis** 

This is a cervicofacial infectious bacterial disease caused by Actinomyces species  such as Actinomyces israelii or A. gerencseriae. It can also be caused by  Propionibacterium propionicus, and the condition is likely to be polymicrobial  aerobic anaerobic infection.

ICD-11 MMS 73   
**1C10.2 Cervicofacial actinomycosis** 

Cervicofacial actinomycosis is the commonest clinical form of actinomycosis, a  sporadically occurring endogenous polymicrobial inflammatory process in which  fermentative actinomycetes of the genera Actinomyces (especially A. israelii and A.  gerencseriae), Propionibacterium and Bifidobacterium act as the principal  pathogens. The typical presentation is a slowly progressive development from  painless tissue infiltration and induration of soft tissues of the face and neck to  multiple abscesses and draining sinus tracts discharging pus. Actinomycosis is a  major factor and indicator of poor prognosis in infected osteoradionecrosis of the  jaws following radiation therapy for head and neck cancer. 

**1C10.3 Primary cutaneous actinomycosis** 

**1C10.Y Other specified forms of actinomycosis** 

**1C10.Z Actinomycosis, unspecified** 

 1C11 **Bartonellosis** 

Any infection caused by the gram-negative bacteria Bartonella. 

***Coded Elsewhere:*** Cat-scratch disease (1B98) 

**1C11.0 Carrion disease** 

Infection by Bartonella bacilliformis which can present as a systemic illness, Oroya  fever, or as a benign skin eruption, verruga peruana. 

**1C11.00** Oroya fever 

A disease commonly caused by an infection with the gram-negative bacteria  Bartonella bacilliformis. This disease is characterised by severe haemolytic  anaemia and transient immunosuppression. This disease may present with fever,  malaise, or jaundice. Transmission is through the bite of infected sandflies from the  genus Lutzomyia. Confirmation is by identification of Bartonella bacilliformis in a  blood sample. 

**1C11.01** Verruga peruana 

A disease caused by an infection with the gram-negative bacteria Bartonella  bacilliformis. This disease is characterised by multiple nodular and red-to-purple  vascular skin lesions, subsequent to Oroya fever. Transmission is through the bite  of infected sandflies from the genus Lutzomyia. 

**1C11.1 Trench fever** 

A disease caused by an infection with the gram-negative bacteria Bartonella  quintana. This disease is characterised by fever, headache, rash, bone pain, or may  be asymptomatic. Transmission is through the bite of infected body lice.  Confirmation is by identification of Bartonella quintana in a blood sample. Bartonella  quintana was formerly known as Rickettsia quintana. 

***Inclusions:*** Quintan fever 

**1C11.Y Other forms of bartonellosis** 

**1C11.Z Bartonellosis, unspecified**

74 ICD-11 MMS    
 1C12 **Whooping cough** 

A disease of the upper respiratory tract, caused by an infection with the gram negative bacteria Bordetella. This disease typically presents with paroxysmal  cough, inspiratory whoop, and fainting or vomiting after coughing. Transmission is  by inhalation of infected respiratory secretions. Confirmation is by identification of  Bordetella from nasopharyngeal samples or sputum, or detection of antibodies  against Bordetella. 

**1C12.0 Whooping cough due to Bordetella pertussis** 

A disease of the upper respiratory tract, caused by an infection of the gram-negative  bacteria Bordetella pertussis. This disease typically presents with paroxysmal  cough, inspiratory whoop, and fainting or vomiting after coughing. Transmission is  by inhalation of infected respiratory secretions. Confirmation is by identification of  Bordetella pertussis from nasopharyngeal samples or sputum, or detection of  antibodies against Bordetella pertussis. 

**1C12.1 Whooping cough due to Bordetella parapertussis** 

A disease of the upper respiratory tract, caused by an infection of the gram-negative  bacteria Bordetella parapertussis. This disease typically presents with a mild clinical  presentation of paroxysmal cough, inspiratory whoop, and fainting or vomiting after  coughing. Transmission is by inhalation of infected respiratory secretions.  Confirmation is by identification of Bordetella parapertussis from nasopharyngeal  samples or sputum, or detection of antibodies against Bordetella parapertussis. 

**1C12.Y Other specified whooping cough** 

**1C12.Z Whooping cough, unspecified** 

 1C13 **Tetanus** 

A disease of the skeletal muscle fibres, caused by an infection with the gram positive bacteria Clostridium tetani. This disease is characterised by muscle  spasms. Transmission is by direct contact of Clostridium tetani to an open wound. 

***Exclusions:*** Obstetrical tetanus (1C14) 

Tetanus neonatorum (1C15) 

 1C14 **Obstetrical tetanus** 

A disease caused by an infection with the gram-positive bacteria Clostridium tetani.  This disease is characterised by a prolonged contraction of skeletal muscle fibres  during pregnancy or within six weeks of termination of pregnancy. Transmission is  by direct contact. 

 1C15 **Tetanus neonatorum** 

A disease affecting neonates, caused by an infection with the gram-positive bacteria  Clostridium tetani. This disease is characterised by systemic muscle spasms that  arise within the first few days after delivery. Transmission is commonly by direct  contact or lack of maternal immunity.

ICD-11 MMS 75   
 1C16 **Gas gangrene** 

Gas gangrene or clostridial myonecrosis is a potentially fatal, rapidly progressive  necrotizing infection of muscle and soft tissue resulting from bacterial invasion of  healthy muscle from adjacent traumatized muscle or soft tissue. The infection  originates in a wound contaminated with bacteria of the genus Clostridium. C.  perfringens accounts for the majority of cases (over eighty percent), while C. novyi,  C. septicum, and C. histolyticum cause most of the other cases. 

 1C17 **Diphtheria** 

A disease commonly of the respiratory system, caused by an infection of the gram positive bacteria Corynebacterium diphtheriae. This disease is characterised by  sore throat, fever, and a pseudomembrane on the tonsils, pharynx, or nasal cavity.  Transmission is by inhalation of infected respiratory secretions, or direct cutaneous  contact. Confirmation is by identification of Corynebacterium diphtheriae from a  throat swab or infected tissue, and by clinical signs. 

**1C17.0 Pharyngeal or tonsillar diphtheria** 

***Inclusions:*** Diphtheritic membranous angina 

**1C17.00** Postdiphtheritic paralysis of uvula 

**1C17.0Y** Other specified pharyngeal or tonsillar diphtheria 

**1C17.0Z** Pharyngeal or tonsillar diphtheria, unspecified 

**1C17.1 Nasal diphtheria** 

**1C17.2 Laryngeal diphtheria** 

localised infection of mucous membranes of the larynx caused by toxigenic strains  of Corynebacterium diphtheriae; it is characterised by the presence of a  pseudomembrane at the site of infection; diphtheria toxin, produced by C.  diphtheriae, can cause myocarditis, polyneuritis, and other systemic toxic effects. 

***Inclusions:*** Diphtheritic laryngotracheitis 

**1C17.3 Cutaneous diphtheria** 

***Exclusions:*** Erythrasma (1C44) 

**1C17.Y Other specified diphtheria** 

**1C17.Z Diphtheria, unspecified** 

 1C18 **Brazilian purpuric fever** 

A disease affecting children, caused by an infection with the gram-negative bacteria  Haemophilus aegyptius. This disease is characterised by fever, nausea, vomiting,  purpuric lesions, and sepsis, that is preceded by conjunctivitis. Transmission may  be by mechanical transmission from infected eye gnats, contact with discharge from  infected individuals, or fomites used near the eyes. Confirmation is by identification  of Haemophilus influenzae from blood. 

***Inclusions:*** Systemic Haemophilus aegyptius infection

76 ICD-11 MMS    
 1C19 **Legionellosis** 

Legionellosis varies in severity from a mild febrile illness to a serious and  sometimes fatal form of pneumonia and is caused by exposure to Legionella  species found in water, and potting mixes. 

Legionellosis is a generic term describing the pneumonic and non-pneumonic forms  of infection with Legionella. 

**1C19.0 Nonpneumonic Legionnaires' disease** 

The non-pneumonic form (Pontiac fever) is an acute, self-limiting flu-like illness  usually lasting 2–5 days. The incubation period is from a few and up to 48 hours.  The main symptoms are fever, chills, headache, malaise and muscle pain (myalgia). 

**1C19.1 Legionnaires disease** 

Legionnaires’ disease, the pneumonic form, has an incubation period of 2 to 10  days (but up to 16 days has been recorded in some outbreaks). Initially, symptoms  are fever, loss of appetite, headache, malaise and lethargy. Some patients may also  have muscle pain, diarrhoea and confusion. There is also usually an initial mild  cough, but as many as 50% of patients can present phlegm. Blood-streaked phlegm  or hemoptysis occurs in about one-third of the patients. The severity of disease  ranges from a mild cough to a rapidly fatal pneumonia. Death occurs through  progressive pneumonia with respiratory failure and/or shock and multi-organ failure. 

**1C19.Z Legionellosis, unspecified** 

 1C1A **Listeriosis** 

A disease caused by an infection with the gram-positive bacteria Listeria. This  disease commonly presents with fever and muscle aches, followed by  gastrointestinal symptoms. 

***Inclusions:*** listerial foodborne infection 

***Coded Elsewhere:*** Neonatal listeriosis (KA61.1) 

**1C1A.0 Cutaneous listeriosis** 

This is a bacterial infection caused by a Gram-positive, motile bacterium, Listeria  monocytogenes. Listeriosis occurs primarily in newborn infants, elderly patients,  and patients who are immunocompromised. 

**1C1A.1 Listerial meningitis or meningoencephalitis** 

A disease of the meninges or brain, caused by an infection with the gram-positive  bacteria Listeria. This disease is characterised by fever, headache, or neurological  deficits. Transmission is through haematogenous spread to the meninges from  ingestion of contaminated food. Confirmation is by identification of Listeria from  cerebrospinal fluid. 

**1C1A.Y Other specified listeriosis** 

**1C1A.Z Listeriosis, unspecified**

ICD-11 MMS 77   
 1C1B **Nocardiosis** 

A disease caused by an infection with the gram-positive bacteria Nocardia. This  disease presents with symptoms depending on the site of infection (commonly lung,  brain, or skin). Transmission is by inhalation of Nocardia from soil or water, or by  direct cutaneous contact. Confirmation is by identification of Nocardia in samples  from affected sites. 

**1C1B.0 Pulmonary nocardiosis** 

A disease of the respiratory system, caused by an infection with the gram-positive  bacteria Nocardia. This disease is characterised by chest pain, haemoptysis, fever,  weight loss, and cough. Transmission is by inhalation of Nocardia from soil or water.  Confirmation is by identification of Nocardia in sputum samples, or lung biopsy. 

**1C1B.1 Cutaneous nocardiosis** 

Cutaneous nocardiosis may be due to direct infection of the skin where it presents  either as a solitary cold abscess or as a lymphangitic process in which infection  spreads up lymphatic channels to form a linear array of suppurative nodules. Skin  involvement is also present in a third of cases of systemic nocardiosis. 

***Exclusions:*** Actinomycetoma due to Nocardia species (1C43) 

**1C1B.Y Other specified forms of nocardiosis** 

**1C1B.Z Nocardiosis, unspecified** 

 1C1C **Meningococcal disease** 

This illness is severe and includes infections of the lining of the brain and spinal  cord (meningitis) and generalised bloodstream infections (bacteraemia with or  without sepsis). 

Meningococcus bacteria are spread through the exchange of respiratory and throat  secretions like spit (e.g., by living in close quarters, kissing). Meningococcal disease  can be treated with antibiotics, but quick medical attention is extremely important.  Keeping up to date with recommended vaccines is the best defence against  meningococcal disease. 

***Inclusions:*** Meningococcal infection 

**1C1C.0 Meningococcal meningitis** 

A condition of the meninges, caused by an infection with the gram-negative bacteria  Neisseria meningitidis. This condition is characterised by high fever, stiff neck,  severe headache, vomiting, purpura, photophobia, and sometimes chills, altered  mental status, or seizures. Transmission is through haematogenous spread to the  meninges after droplet transmission or direct contact. Confirmation is by  identification of Neisseria meningitidis in CSF (cerebrospinal fluid), for example, by  agglutination test or polymerase chain reaction. 

***Inclusions:*** Meningitis due to Neisseria meningitidis

78 ICD-11 MMS  